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Acute traumatic coagulopathy (ATC) is a recently identified entity describing an early impairment of haemostasis after injury. Retrospective observational studies have associated it with a significant increase in patient morbidity and mortality. It does not appear to be caused by conventional mediators of haemorrhagic coagulopathy, such as iatrogenic haemodilution or hypothermia. Rather, it has been postulated that it is endogenous systemic anticoagulation modulated by activation of the protein C pathway in response to shock and tissue injury. 

The aims of this thesis were to characterise the aetiology and clinical significance of ATC and test the hypothesis that activated protein C plays a functional role in the pathophysiology of this condition. A retrospective analysis of patients admitted to 5 major international trauma centres was performed. Admission prothrombin times were correlated with aetiological variables and clinical outcomes. A structured literature review was subsequently conducted to identify the strengths and weaknesses of existing animal models of traumatic coagulopathy. Novel rodent (rat and mouse) models of ATC were then developed to elucidate how it develops.
 
Clinical data on 3646 trauma patients identified a significant and dose-dependent increase in mortality and transfusion requirements with admission prothrombin time ratio > 1.2. The incidence of ATC co-associated with both the degree of tissue injury and the depth of haemorrhagic shock. Literature review identified a general failure of animal models to accurately simulate the clinical trajectory of injury. Specifically, only one (mouse) model of ATC was identified. Novel rodent models of ATC were developed that demonstrated endogenous coagulopathy in response to 60 minutes of haemorrhagic shock, with or without significant tissue injury. This was mediated predominantly by autogenous haemodilution and activated protein C anticoagulation.

Acute traumatic coagulopathy is an endogenous impairment of haemostasis that develops in response to severe haemorrhagic shock. Manipulation of the protein C pathway may represent a novel therapeutic strategy for reducing blood loss and improving outcomes after injury.
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aPTT		activated partial thromboplastin time
ARDS		acute respiratory distress syndrome
ATC		acute traumatic coagulopathy
ATLS		advanced trauma and life support
BD		base deficit
Ca2+		ionised calcium





ECPR		endothelial cell protein C receptor





































PAR-1		protease activated receptor 1
PL		phospholipid








TAFI		thrombin activatable fibrinolysis inhibitor
TF		tissue factor
TFPI		tissue factor pathway inhibitor
THAM		trometamol; tris-hydroxymethyl aminomethane
TIC		trauma induced coagulopathy
TNF		tumour necrosis factor alpha




































































1.1. 	Trauma: the disease

Physical trauma is a leading cause of death and disability worldwide. Approximately 10% of all deaths occur as a result of injury and in the UK it accounts for over 17,000 deaths annually (2007). It is predominantly a disease of young adults and kills more people aged 15-44 than any other, with an average of 36 life years lost per trauma death (Chiara and Cimbanassi 2003). The skew of prevalence towards the young has a wider impact than mortality statistics alone can illustrate. For each trauma fatality there are two survivors with serious or permanent disability (2007). Worldwide, over 1.8 billion disability adjusted life years are lost annually as a consequence of trauma (2008). In addition to the personal and emotional effects, trauma inflicts a massive financial burden in terms of direct healthcare costs as well as loss of productivity to society. 

The injured population can be divided into military and civilian cohorts that exhibit comparable and contrasting characteristics. Military casualties are almost exclusively young men in their twenties, the majority of whom are killed or injured by a penetrating missile  ADDIN EN.CITE (Kelly, Ritenour et al. 2008). The origin of such a missile (e.g. explosion, gunshot) depends largely upon the nature of the battle, enemy tactics and the geography of the combat theatre. Whilst there is also a higher prevalence of males in civilian trauma cohorts, the gender ratio is more balanced and the average age of the victim tends to be higher. A blunt mechanism of injury predominates and road traffic accidents are the commonest cause (2000; Evans, van Wessem et al. 2010). Specific demographics depend substantially upon the location (e.g. urban versus rural) and country under study (e.g. developed versus developing). 





Fig. 1.1. Major causes of death in 4 seminal epidemiological studies of civilian trauma.  ADDIN EN.CITE (Baker, Oppenheimer et al. 1980; Shackford, Mackersie et al. 1993; Sauaia, Moore et al. 1995; Evans, van Wessem et al. 2010). MOF, multiple organ failure.

As well as being a major cause of early mortality through exsanguinations, traumatic haemorrhage coupled with resuscitation yields a systemic ischaemia-reperfusion syndrome contributing to post-injury morbidity and late mortality. The degree of blood lost and depth of subsequent tissue hypoperfusion correlates directly with the incidence of sepsis, MOF, length of ITU and overall hospital stay in initial survivors  ADDIN EN.CITE (Chaudry and Ayala 1993; Davis, Parks et al. 1996; Durham, Moran et al. 2003). Furthermore, transfusion of allogenic blood replacement products during resuscitation inflicts a dose-dependent increase in the extent of these outcomes independent of shock severity (Malone, Dunne et al. 2003). Thus, minimising blood loss is a clinical priority after traumatic injury.





Injury to the vascular endothelium precipitates temporary reflex local vasoconstriction to reduce blood flow and limit haemorrhage volume. Exposure of the subendothelial matrix, which contains cells, collagen, and Von Willebrand factor (VWF), causes flowing platelets to roll and tether to the site of injury. Platelets then adhere to this matrix via a collagen receptor and glycoprotein Ib (GPIb), an adhesive receptor that binds to VWF (Jackson, Nesbitt et al. 2009). Following initial adhesion, rapid signal transduction leads to platelet activation, cytoskeletal shape change, secretion, and presentation of integrins that recruit additional platelets. Release and local accumulation of soluble agonists such as adenosine diphosphate (ADP), Thrombin, thromboxane A2 (TxA2), Epinephrine and Serotonin enhances platelet aggregation and/or prolongs local vasoconstriction (Rivera, Lozano et al. 2009). 

Rapid accumulation of a platelet plug represents ‘Primary Haemostasis’ and is alone capable of sealing small endothelial lesions. However, activated platelets and subendothelial matrix also express tissue factor, a thromboplastin capable of triggering a cascade of procoagulant enzymes that culminate in the formation of a fibrin mesh  ADDIN EN.CITE (Mackman 2004; Mezzano, Matus et al. 2008). This mesh stabilises and structurally supports the developing platelet plug, a process known as ‘Secondary Haemostasis’. Its clinical importance is demonstrated in haemophiliac patients who have inadequate function of one or more procoagulant enzymes and can experience uncontrollable haemorrhage in response to relatively minor injury.  





Fig. 1.2. The cascade model of coagulation. Adapted from (Hoffman and Monroe 2001). HMK – high molecular weight kininogen. PK, prekallikrein; PL, phospholipid; Ca+2, ionised calcium.









           

Fig. 1.3. A. Initiation Phase. B. Amplification phase. C. Propagation Phase. Adapted from (Hoffman 2003). TF, tissue factor

1.3.1.	     Trauma Induced Coagulopathy (TIC)
Coagulopathy is a disease or condition affecting the blood’s ability to coagulate (Coagulopathy 2010). It has two vectors and both are seen in trauma patients with variable magnitude and chronology  ADDIN EN.CITE (Hoyt, Bulger et al. 1994; Schreiber, Differding et al. 2005; Tieu, Holcomb et al. 2007; Park, Martini et al. 2009). Hypercoagulability has been implicated as a factor in the pathophysiology of increased thromboembolism after trauma (Meissner, Chandler et al. 2003). However, most acutely threatening to an exsanguinating trauma patient is a bleeding diathesis. 

Impairments of haemostasis after trauma results in difficult haemorrhage control, increased transfusion requirements and worse mortality (Hoyt, Bulger et al. 1994). Acute blood loss proceeds at a greater rate in the presence of systemic coagulopathy. Oozing of blood from blunt tissue injuries, vascular access sites and surgical incisions is not amenable to surgical control and may threaten viability. This uncontrollable haemorrhage may force the early termination of operations and result in the sacrifice of organs or limbs in order to preserve life. It also worsens outcomes from traumatic brain injury by an increased potential for intracranial hemorrhage and secondary neuronal loss (Hess, Brohi et al. 2008). 
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Fig. 1.4. Illustration of methods for PT and aPTT determination. Respective reagents are added to the sample plasma in a cuvette to initiate coagulation. As fibrin polymerises it impedes the path of the spinning metal ball and halts the counter. Alternative detection systems include optical or electrical impedance.

A platelet count and fibrinogen concentration assay usually supplement the routine tests of coagulation. However, the usefulness of a platelet count is limited without any additional assessment of their function and using either to guide therapy is made difficult by a paucity of evidence for the clinical relevance of abnormal results. Recently there has been a renewed interest in the use of thromboelastometry for trauma care. These machines (ROTEM and TEG) employ a rotating pin to measure the viscoelastic properties of ex-vivo whole blood as it clots inside a small cuvette. They provide an assessment of the speed and strength of clot formation as well as fibrinolytic degradation over time. Research studies suggest their superiority to routine tests of coagulation for diagnosing TIC  ADDIN EN.CITE (Kheirabadi, Crissey et al. 2007; Johansson, Stissing et al. 2009). Further prospective trials are warranted to validate a transfusion protocol using them. 

Coagulopathy associated with trauma has been recognised for decades and is a constituent of the “triad of death”, together with hypothermia and acidosis. Classically it has been understood as due to loss, dilution or dysfunction of the coagulation proteases. Loss is explained as being due to bleeding or consumption, dilution from fluid administration and massive transfusion, while protease dysfunction results from hypothermia and the effect of acidosis on enzyme function. However, in a severely injured trauma patient these variables frequently co-exist and determining the independent detrimental effect of each is difficult.

An attempt to delineate the clinical risk factors associated with coagulopathy has been made in a cohort of trauma patients receiving massive transfusion (more than 10 units of red blood cells) (Cosgriff, Moore et al. 1997). Four major risk factors for coagulopathy were identified and their associated odds ratios were: pH <7.1 (RR = 12.3); core temperature <34°C (RR = 8.7); an injury severity score (ISS) >25 (RR = 7.7); a systolic blood pressure < 70 mm Hg (RR = 5.8). Patients with no risk factors had a 1% risk of coagulopathy, and those with a single risk factor a 10 to 40% risk, with injury severity per se being associated with the lower 10%. Combinations of the risk factors were associated with increasingly higher risk until patients with all four risk factors had 98% risk of developing coagulopathy. This was a landmark study and reaffirmed the bi-directional association between metabolic failure and coagulopathy. However, a restrictive definition of coagulopathy (PT or aPTT time more than two times that of normal laboratory control) and prospective inclusion of patients receiving massive transfusion meant that results were based on a multiple logistic regression model containing just 58 data sets, only 27 (47%) of which exhibited the outcome under study. In civilian practice only a small percentage (<5%) of trauma victims receive a massive transfusion of allogenic blood and more pathological importance is attributed to the volumes of crystalloid and plasma infused. Therefore, it is difficult to generalise these findings to the extended trauma cohort who may develop less severe coagulopathies but still have worse morbidity and mortality.

1.3.2. 	Loss: Haemorrhage, Consumption & Disseminated Intravascular Coagulation (DIC)

Haemorrhage predisposes to coagulopathy by depleting clotting factors at a rate far exceeding the production or reserve of the coagulation system. The amount of clotting factors delivered to injured tissues subsequently diminishes along with perfusion. Survival necessitates restoration of intravascular volume through autogenous transcapillary refill of protein poor extravascular fluid and exogenous resuscitation. Contemporary transfusion algorithms entail the administration of substances with a combined haemostatic capacity inferior to that of the original blood lost  ADDIN EN.CITE (O'Shaughnessy, Atterbury et al. 2004; Therapies 2006). Therefore, haemodilution and coagulopathy ensue as a product of the volume of haemorrhage and resuscitation required.

Local consumption of clotting factors occurs after trauma as a consequence of tissue injury induced activation of coagulation. A transition from ‘idling’ thrombin generation to the amplification and propagation phases of coagulation proceeds as platelets and FVIII/vWF spill out into the extravascular tissues and adhere to TF bearing cells exposed at the site of injury (Hoffman 2003). The end product, a fibrin and platelet rich clot, impedes bleeding and provides a physical and inflammatory network for subsequent tissue repair (Mutsaers, Bishop et al. 1997). There is also evidence that intravascular thrombi develop in response to tissue injury and can occur in the absence of haemorrhage. 





Fig. 1.5. Cine-tracing of a motion picture of blood flowing through crushed monkey omentum. Art, artery; V, vein; AVA, arteriovenous anastamosis; FC, fat cells; Th, thrombosed venule; WC, white cells; FB, fluid blood; PR, precipitated blood; SLUDGE, masses of precipitated-agglutinated blood. Adapted from (Knisely, Eliot et al. 1945)
 
Although stable whilst circulating as their zymogen, activated coagulation factors have a short half-life and are rapidly and irreversibly eliminated by their natural inhibitors (Mann 1999). Logically, the amount of local coagulation factor consumption would be proportional to the degree of tissue injury. In theory, massive trauma with extensive local coagulation factor consumption could deplete procoagulant resources and lead to a clinical coagulopathy, even in the absence of significant haemorhagic losses. However, the concentration and functional activity of circulating coagulation factors has not been measured as a response to trauma severity alone. Therefore, it is difficult to estimate what independent contribution tissue injury induced local activation of coagulation makes to TIC.





Fig 1.6. Clinical conditions associated with overt DIC. Adapted from (Taylor, Toh et al. 2001).

There are three published scoring systems for DIC  ADDIN EN.CITE (Kobayashi, Maekawa et al. 1983; Taylor, Toh et al. 2001; Gando, Wada et al. 2005). They are broadly similar and all require evidence of haemostatic exhaustion combined with the depletion of key coagulation factors and molecular verification of fibrin precipitation. An underlying disorder known to be associated with DIC is a conditio sine qua non for the use of either algorithm.

That trauma is a primary cause of DIC, and the mechanism through which it develops, is a matter of some current scientific debate  ADDIN EN.CITE (Hess, Brohi et al. 2008; Gando 2009). Early studies suggesting an association between the two did not differentiate DIC from dilutional coagulopathy. More recent studies have assessed the activation of coagulation shortly after trauma, before any influence from haemodilution  ADDIN EN.CITE (Blombäck, Eklund et al. 1985; Gando, Tedo et al. 1992; Gando, Nakanishi et al. 1995; Sawamura, Hayakawa et al. 2009; Sawamura, Hayakawa et al. 2009). They all describe small cohorts of critically ill trauma patients who develop an acute impairment of haemostasis that can be diagnosed using DIC scoring systems. A diagnosis of DIC was found to be associated with an increased risk of acute respiratory distress syndrome (ARDS), MOF and death. In contrast to septic patients with DIC, these trauma patients exhibited hyperfibrinolysis similar to that seen with haemopoietic malignancies. To reflect this dichotomy, DIC has been subdivided into fibrinolytic (hemorrhagic) and antifibrinolytic (thrombotic) phenotypes.  

Whilst some bleeding trauma patients may be diagnosed and their prognosis categorised with DIC scoring systems, this is of limited clinical use because there is no cure and treatment is directed at the underlying pathology. The sensitivity of DIC scoring systems for identifying acutely coagulopathic trauma patients with an increased mortality risk is unknown. There may be a significant proportion of injured patients with a clinically significant coagulopathy that do not meet the criteria for a diagnosis of DIC. Furthermore, if some conventional therapies for DIC (heparin, antithrombin, activated protein C, etc.) were administered to patients with TIC they would exacerbate ongoing haemorrhage.

A syndrome initiated by such diverse underlying pathologies could be expected to have substantial variation in pathophysiology. Logically, release of thromboplastins from injured tissues into the systemic circulation could be expected to induce disseminated activation of coagulation after trauma. Indeed, elevated circulating TF has been observed in patients with DIC  ADDIN EN.CITE (Gando, Nanzaki et al. 2001) and intravenous administration of TF alone can induce DIC in animal models  ADDIN EN.CITE (Warr, Rao et al. 1990; Asakura, Suga et al. 2003). However, physically injured tissues may not be the sole, or even dominant, source of TF for activation of coagulation after trauma. Septic patients also develop DIC through a TF dependent manner and the majority of these have not experienced any tissue injury at all. Rather, in these patients there is extensive generation of pro-inflammatory cytokines (IL-1, IL-6 and TNF) that mediate pathological TF expression on endothelium and a range of circulating cells (eg. neutrophils, macrophages) (Levi and van der Poll 2010). 

An inflammatory cytokine response with elevation of IL-1 and TNF-alpha has been observed in trauma patients soon after injury, with significantly higher levels occurring in patients with DIC, despite a similar rate of septic complications (Gando, Nakanishi et al. 1995). This response could be caused by the tissue trauma itself and there has been a degree of dose-dependency shown in clinical studies by IL-1 and IL-6 (Baigrie, Lamont et al. 1992). Clinical and experimental studies have also demonstrated that haemorrhgic shock can exacerbate the cytokine response to trauma and that it is a potent stimulant of inflammation on its own  ADDIN EN.CITE (Ayala, Perrin et al. 1990; Ayala, Wang et al. 1991; Roumen, Hendriks et al. 1993). This could translate into an increased propensity to coagulate, which would appear an appropriate physiological response to blood loss. Indeed, William Hewson, a prominent 18th century physiologist who studied the properties of blood observed that ‘the blood which issued last coagulated first in animals and man being venesected.’

Whether or not blood loss alone is capable of producing a gross impairment of the haemostatic system, either through an inflammatory cytokine stimulated consumptive coagulopathy or other mechanism, is difficult to establish. Acute coagulation responses to penetrating and blunt mechanisms of trauma (associated with relatively high and low amounts of tissue damage, respectively) have never been studied separately. Using a low ISS as a quantitative marker of low tissue injury is not perfect as it was designed to correlate with risk of death and is not a linear scale. There are other non-traumatic clinical bleeding conditions in which acute non-dilutional coagulopathy have been identified, such as ruptured abdominal aortic aneurysm or gastrointestinal bleeding. However, patients experiencing these usually have co-morbidities, such as an inflammatory thrombus or liver disease, which may profoundly influence the haemostatic effects of the haemorrhage.

Animal models using healthy subjects exposed to little, if any, tissue injury have offered contrasting evidence as to the independent effects of haemorrhage on coagulation. One of the first studies, performed on dogs, involved femoral artery cannulation under anaesthesia followed by haemorrhage to a blood pressure of 50 mmHg for 90 minutes, followed by a further bleed to 30 mmHg for 45 minutes (CROWELL and READ 1955). The clotting time of serial 1 ml samples of blood was seen to rapidly shorten after the onset of haemorrhage and blood pressure failed to recover fully with return of the blood (this was termed ‘irreversible shock’ and was associated with the identification of multiple intravascular emboli). Pre-treatment with low and high dose heparin produced dose-dependent protection from this hypercoagulability and improved survival. Similarly, Hardaway et al documented a linear fall in silicone clotting times of dogs subjected to successive bleeds of 100 mls each (HARDAWAY, BRUNE et al. 1962). This was associated with a 45% drop in fibrinogen and haemorrhagic necrosis of the bowel, liver and pancreas. Interestingly, upon re-transfusion of the haemorrhaged blood (which had been passed through an ion exchange resin for decalcification) the clotting times prolonged beyond the pre-haemorrhage level and in some cases blood became incoagulable. This effect was reversible with protamine and was attributed to the production of endogenous heparinoids (the calcium diluting effect of returning decalcified blood was not clarified). A biphasic coagulation response to haemorrhagic shock has also been observed in rabbits (TURPINI and STEFANINI 1959). They showed an early hypercoagulability with the generation of a thromboplastin that could accelerate clotting ex vivo in normal blood, followed by a hypocoagulability associated with a fall in many clotting elements (‘labile factor’, prothrombin, platelets etc.).

In contrast, no hypercoagulability was demonstrated in a baboon model of haemorrhagic shock (Herman, Moquin et al. 1972). Blood was shed over a fifteen-minute period to a mean arterial pressure of 60 mmHg that was maintained for 60 minutes, before a further bleed to 40 mmHg for 5 minutes. There was a drop in haematocrit and platelets, as well as a trend toward a prolonged PT and aPTT, which was consistent with mild haemodilution produced by administration of Ringer’s lactate to stabilise the blood pressure. Similarly, in another rabbit model, whereby 35 mls of blood (approximately 30% circulating blood volume) was removed over 70 minutes, there were no coagulation changes except a small fall in fibrinogen due to dilution. 

There are interspecies differences in coagulation systems that may affect experimental responses to haemorrhagic shock (Siller-Matula, Plasenzotti et al. 2008). The depth and direction of the coagulation changes may also depend upon the severity of the shock induced, the time point at which sampling occurs, as well as the test used to measure it. Lastly, most models published have involved some degree of fluid/blood infusion in order to maintain target blood pressures. Therefore, haemodilution may have played a small or substantial part in the coagulation changes described. 

1.3.3. 	Dilution: Crystalloids & Blood Product Transfusion


Severe haemorrhage may produce circulatory shock, a condition in which tissue perfusion is insufficient to meet cellular metabolic needs. Previous Advanced Trauma & Life Support (ATLS) guidelines have recommended treating or preventing hypovolaemic shock by the initial administration of up to 2 litres of crystalloid fluid. Adherence to this recommendation presents at least three physiological problems. Firstly, crystalloids offer no oxygen carrying capacity. Therefore, although the perfusion pressure may improve with an increase in circulating volume, haemoglobin concentration decreases with dilution. Secondly, although they are isotonic, crystalloids rapidly distribute throughout the vascular spaces and circulating volume diminishes with time. Thirdly, crystalloids contain no coagulation factors. Therefore, any crystalloid administration would impair haemostatic function during haemorrhagic shock. However, this assumption is not undisputed. Ruttman et al have demonstrated that rapid small volume haemodilution with normal saline can produce hypercoagulability in vitro (Ruttmann, James et al. 1996), in healthy volounteers (Ruttmann, James et al. 1998), and in patients undergoing peripheral vascular surgery (Ruttmann, James et al. 2002). Their findings were attributed to an imbalance in the dilutional effect of saline on procoagulant and anticoagulant pathways resulting in a predominance of the former. More specifically, they single out depletion of antithrombin as the culpable cause. Whilst their results have been validated in further studies, their importance is limited by the fact that hypercoagulability was only demonstrated using thromboelastographic parameters. Other tests of coagulation, such as PT or aPTT, indicated no such effect. Whether or not the context and findings of these studies are comparable with and relevant to the in vivo haemostatic millieu after trauma is debatable. 

Mathematically, administration of crystalloid fluid during haemorrhage would be expected to prolong measures of haemostasis and cause a clinical coagulopathy (Hirshberg, Dugas et al. 2003). This is supported by in vitro studies that demonstrate dose-dependent impairments of thrombin generation, platelet activation and fibrin formation with Ringer’s lactate or normal saline (Brummel-Ziedins, Whelihan et al. 2006). Perhaps most convincing is data from a clinical trauma study that reported a significant prolongation of coagulation times in patients who received pre-hospital resuscitation with crystalloid as compared with those who did not (Faringer, Mullins et al. 1993). A balanced review of the literature might conclude that small volumes of crystalloid, perhaps up to 20% of circulating volume, could improve coagulation function whereas further dilution would impair it. Regardless of the degree of consensus concerning crystalloid, it is clear that most colloid solutions have a negative impact on coagulation over and above any dilutional effect and should not be used in trauma resuscitation (Coats, Brazil et al. 2006).

Ongoing haemorrhage with shock that is unresponsive to small volume crystalloid administration should be replaced with blood products. Historically this was achieved by direct donor to receiver transfer or by administering whole blood stored in anticoagulant. Development of technology for fractionating blood into its constituent parts improved the storage and availability of blood products and since the Second World War this has been the predominant mode of practice for most blood services. However, haemorrhage transfusion protocols developed to guide the delivery of these products most commonly recommended the administration of packed red blood cells to target a haemoglobin concentration of greater than 10 g/dl after trauma. Fresh frozen plasma (FFP) was not deemed required until the international normalized ratio (INR) had exceeded 1.5, and platelets when there number dropped below 50,000 cells/mm3  ADDIN EN.CITE (Pathologists 1994; O'Shaughnessy, Atterbury et al. 2004; Therapies 2006). Hence, it was not considered necessary to replace clotting factors until a dilutional coagulopathy was established. 

There is an increasing body of evidence indicating that these protocols cannot and do not achieve normal haemostasis in trauma patients requiring a massive transfusion. A recent study from Houston examined the effectiveness of their pre-intensive care unit (ICU) massive transfusion protocol at correcting coagulopathy in severely injured and shocked trauma victims  ADDIN EN.CITE (Gonzalez, Moore et al. 2007). Ninety-seven patients receiving 10 or more units of packed red blood cells (PRBC) during hospital day 1 had an admission INR of 1.8 ± 0.2. Adherence to their massive transfusion protocol with administration of 5 units of FFP (commenced after the 6th unit of PRBC) together with 12 units of PRBC failed to correct this coagulopathy despite good management of hypothermia and acidosis. By the time of ICU admission 6.8 ± 0.3 h later, coagulopathy persisted (INR 1.6) and this was identified as an independent predictor of mortality in this cohort.

In the absence of timely and robust tests of coagulation, blood component replacement in severely bleeding patients is usually performed empirically based on the number of units of PRBC given. This is often expressed as a FFP: PRBC ratio. Whole blood contains plasma equivalent to a ratio of 1:2 FFP: PRBC (6 units of whole blood is equivalent to 6 units of PRBCs, 3 units FFP and 1 of platelets) (Geeraedts, Demiral et al. 2007). There are no recommended values for optimal FFP: PRBC administration in currently available guidelines and practice varies with common ratios of between 1:3 and 1:8. However, data emerging from computer models and observational studies of trauma resuscitation protocols indicate that earlier and more aggressive treatment of coagulopathy with plasma and platelets could improve survival  ADDIN EN.CITE (Hirshberg, Dugas et al. 2003; Ho, Dion et al. 2005) A retrospective study of The United States Army Joint Theater Trauma Registry was performed to analyse the effect of different plasma to red blood cell ratios on the mortality of trauma patients admitted to combat support hospitals in Iraq between November 2003 and September 2005  ADDIN EN.CITE (Borgman, Spinella et al. 2007). Two hundred and forty-six patients received 10 or more units of red blood cells (PRBC or fresh whole blood) and they were grouped according to the ratio of plasma to red blood cells transfused. The low ratio group median was 1:8, the medium ratio group median was 1:2.5, and the high ratio group median was 1:1.4. Overall mortality rates were 65%, 34% and 19% and haemorrhage mortality rates were 92.5%, 78% and 37%, respectively. Upon logistic regression, plasma to red blood cell ratio was independently associated with survival (odds ratio 8.6).

A study of 45 massively transfused patients admitted to Irvine Medical Centre, California, USA reported the plasma to red blood cell ratio for survivors was 1:1.8 compared with 1:2.5 in non-survivors (p = 0.06) (Cinat, Wallace et al. 1999). Implementation of a Trauma Exsanguinations Protocol, with aggressive FFP and platelet replacement, at The Vanderbilt University Medical Centre, Nashville, USA has produced a 74% reduction in the odds of mortality (p = 0.001) ADDIN EN.CITE (Cotton, Gunter et al. 2008). This was associated with a lower overall blood product consumption (p = 0.015). So far, these studies documenting benefits associated with aggressive clotting component replacement have been retrospective. Furthermore, a survivor bias probably exists whereby more critically ill trauma victims die before thawed plasma becomes available and consequently receive less. A randomised clinical trial of different FFP:PRBC ratios is warranted to address these limitations and improve evidence for a change in practice.

1.3.4. 	Dysfunction: Hypothermia & Acidosis


Mild hypothermia is very common in trauma patients and probably has minimal clinical impact (Hess, Brohi et al. 2008). Contemporary studies of clinically important hypothermia (< 35C) have reported an incidence rate of 1.5 – 8%, and this is dependent upon the characteristics of the trauma cohort, their environment, and the timing of the sample measurement  ADDIN EN.CITE (Beekley and Watts 2004; Martin, Kilgo et al. 2005; Wang, Callaway et al. 2005). The cause of hypothermia is multifactorial. From the time of injury, trauma itself alters the normal central thermoregulation and blocks the shivering response (Tsuei and Kearney 2004). Bleeding with subsequent systemic hypoperfusion creates an oxygen deficit and impairs heat-producing respiration, particularly in the large cutaneous and skeletal muscle beds. Trauma patients, who are frequently under the influence of alcohol, are then invariably immobilised with consequent loss of muscle activity and undressed to facilitate inspection and management of wounds.
  




Figure 1.7. Percentage mortality at each admission body temperature. Body temperature rounded to nearest integer. n = 700 304. Adapted from (Martin, Kilgo et al. 2005)

That hypothermia is intrinsically harmful to trauma patients is not obvious biologically. Despite the negative physiologic changes induced by hypothermia and the potential for complications in the trauma patient, induced hypothermia has been noted historically to improve outcomes in animal studies  ADDIN EN.CITE (Wu, Stezoski et al. 2003; Nozari, Safar et al. 2004) and certain clinical situations  ADDIN EN.CITE (Group 2002; Hoesch and Geocadin 2007). It has been postulated that this is secondary to a reduction in the metabolic demands of respiring cells with a smaller oxygen deficit and less ischaemia-reperfusion injury. However, the experiments that show benefit from induced hypothermia have not featured uncontrolled haemorrhage, which is ubiquitous in severely injured polytrauma patients. Hypothermia is known to have a significant negative impact on haemostasis and it may be that any improvement in survival from cell ‘hibernation’ is outweighed by the detriment of additional blood loss. Support for this hypothesis is found in a clinical study where investigators reported a 2.4-fold increase of blood loss in post-laparotomy patients whose body temperature was 33.8 ± 0.5°C as compared with that of patients whose temperature was 36.1 ± 0.7°C, despite similar injury severity (Bernabei, Levison et al. 1992).






Fig. 1.8. Effect of temperature on aPTT clotting time. The aPTT in seconds of normal pooled plasma is plotted against the temperature. *Statistically significantly different from that at 37°C at the p < 0.05 level. The data shown are the mean and SD of four separate assays. ‡Statistically significantly different from that at 33°C at the p < 0.05 level. Adapted from (Wolberg, Meng et al. 2004).

Platelet function is probably even more sensitive to hypothermia, with low temperatures decreasing activation. In vitro, microscopic examination identified that the average size of aggregates formed by thrombin-activated platelets is decreased by 40% at 33°C (Wolberg, Meng et al. 2004). At 37°C the platelets aggregated into large clumps on a background of scattered individual platelets. By contrast, the “aggregates” at 33°C appeared to consist primarily of platelets in groups of two or three. The adhesion of platelets to a surface under flow conditions was also dramatically reduced at 33°C in a fashion similar to what was seen with aggregate formation. The surface coverage by adherent platelets was reduced by 33% at 33°C. This is due to a reduced effect of vWF traction on GPIb/IX, which mediates initial adhesion and activation, and activation is essentially absent below 30C (Kermode, Zheng et al. 1999). The in vivo effect of this pathology was demonstrated in a baboon model in which the bleeding time of upper limb incisions increased from 3.1 to 6.9 minutes by local cooling of the arm from 34.6 to 27.6C (Valeri, Feingold et al. 1987).

Acidosis is a common event in trauma, typically produced by low-flow shock states and excess ionic chloride administered during resuscitation (Hess, Brohi et al. 2008). Determining the independent haemostatic effects of acidosis is made difficult by the absence of clinical conditions that feature it in isolation. In trauma studies it is reported as a measure of systemic hypoperfusion and cannot be separated from other the haemostatic effects of hypovolaemic shock. In vitro studies have demonstrated impaired clotting enzyme activities in response to acidosis (Wolberg, Meng et al. 2004). When pH was reduced from 7.4 to 7.0, Meng et al reported that the activities of factor VIIa and FVIIa/TF complex on phospholipid vesicles decreased by more than 90% and 60%, respectively (Meng, Wolberg et al. 2003). 

Ex-vivo spiking tests and in vivo acid infusion experiments have been performed, which have reported inconsistent results. Artificial acidification of blood from 6 healthy volunteers significantly prolonged all thromboelastometry parameters as well as the PT (from 11.4 to 12.1 s; P = 0.044) and aPTT (from 29.3 to 45.0 s; p = 0.028)  ADDIN EN.CITE (Ramaker, Meyer et al. 2009). However, the pH of these samples was 6.95, a degree of acidosis that is lower than seen in the vast majority of trauma patients. A similar experiment by Dirkmann et al found that acidosis of between 7.00 and 7.37 failed to exert any significant effects on thromboelastometry parameters under normothermic (36°C) conditions (Dirkmann, Hanke et al. 2008). However, acidosis had significant effects under hypothermia. At 33°C, an additional decrease in pH significantly worsened most thromboelastometry related variables. 

A decrease in PT and aPTT has been reported in dogs after the infusion of 1 mol/l of lactic acid  ADDIN EN.CITE (Crowell and Houston 1961; Broersma, Bullemer et al. 1970). Conversely, an increase in PT and aPTT clotting times and decreased fibrinogen levels and platelet counts were reported by Dunn et al in dogs after the infusion of hydrochloric acid solution (Dunn, Moore et al. 1979). When pH was reduced from 7.4 to 7.1 in pigs, Martini et al showed that thrombin generation decreased to 47% of control values, while fibrinogen concentration decreased by 18% (Martini, Pusateri et al. 2005). The depletion of fibrinogen was attributable to accelerated degradation rather than impaired synthesis (Martini and Holcomb 2007). These decreases were also associated with a 47% increase in splenic bleeding time. On balance it appears that acidosis has a negative effect on the coagulation system. However, although acidosis can be corrected by the administration of buffer solutions, this does not correct the coagulopathy  ADDIN EN.CITE (Martini, Dubick et al. 2006; Martini, Dubick et al. 2007), implying that the acid effect is more than simply a physical reduction in protease activity.

1.3.5. 	Summary of TIC






Fig. 1.9. Simplified illustration of post-traumatic coagulopathy as a secondary or resultant event. Adapted from (Spahn and Rossaint 2005).

However, a series of research studies have demonstrated that some trauma patients arrive in the emergency department with a coagulopathy already established. These patients have generally had short transfers with little time to become hypothermic or receive significant exogenous fluid resuscitation. This has generated significant debate as to whether some trauma victims may develop an endogenous acute coagulopathy.

1.4.1. 	   Acute Traumatic Coagulopathy (ATC)

The first landmark report of the existence of ATC was in a retrospective study of the admission coagulation results of 1088 trauma patients transferred to The Royal London Hospital by air ambulance (Brohi, Singh et al. 2003). 24% arrived in the emergency department with a clinically significant coagulopathy already established and they were four times more likely to die than those presenting with normal clotting parameters. Subsequent studies performed by independent research groups on a total of over 45,000 patients have confirmed the existence of this early coagulopathy  ADDIN EN.CITE (MacLeod, Lynn et al. 2003; Brohi, Cohen et al. 2007; Maegele, Lefering et al. 2007; Rugeri, Levrat et al. 2007; Niles, McLaughlin et al. 2008; Hess, Lindell et al. 2009). All of these studies reported a strong association between acute coagulopathy and mortality and identified it as an independent risk factor for death (MacLeod, Lynn et al. 2003). It has also been associated with longer intensive care and hospital stays. Patients are more likely to develop acute renal injury (Rugeri, Levrat et al. 2007) and MOF  ADDIN EN.CITE (Maegele, Lefering et al. 2007), have fewer ventilator-free days  ADDIN EN.CITE (Brohi, Cohen et al. 2007; Maegele, Lefering et al. 2007) and there is a trend towards an increased incidence of acute lung injury  ADDIN EN.CITE (Maegele, Lefering et al. 2007). 

Study of the literature identifies a small number of earlier reports of coagulopathy in patients shortly after injury. Most of these involved patients with isolated head injury  ADDIN EN.CITE (Strinchini, Baudo et al. 1974; Pondaag 1979). However, two reports identify ATC in polytrauma victims. The first was a report on 240 casualties of the Vietnam War. 30 cases developed a prolongation of either their PT or aPTT between injury and emergency helicopter evacuation (Simmons, Collins et al. 1969). The second involved 180 patients who suffered traumatic death at a teaching hospital in Los Angeles, California, during 1981/2 (Ordog, Wasserberger et al. 1985). All except 5 had developed a coagulopathy before emergency department admission. In both reports samples were drawn prior to any resuscitation and the authors concluded that coagulopathy was a product of DIC and/or haemorrhagic losses. 





Injury severity is closely associated with the degree of acute coagulopathy seen after trauma. In the London study only 10.8% of patients with an ISS of 15 or below had a coagulopathy, compared with 33.1% of those with an ISS over 15 (Brohi, Singh et al. 2003). This figure increased to 61.7% for those with an ISS over 45. In the larger German study a coagulopathy was evident in 26% of patients with an ISS 16-24, in 42% of patients with an ISS 25-49, and in 70% of patients with an ISS > 50, respectively  ADDIN EN.CITE (Maegele, Lefering et al. 2007). However, not all patients who are severely injured present with a coagulopathy, tissue trauma alone does not appear sufficient.














Data on the acute coagulation factor responses to trauma and shock is sparse and the early pathological effects of depletion and consumption are unclear. Fibrinolysis is activated early after injury, increases with higher injury severity and is exacerbated by shock (Brohi, Cohen et al. 2008). However, this does not appear to correspond with a depletion of the major coagulation factors. Although one study found low fibrinogen levels in coagulopathic patients (median 0.9 gL-1) (Rugeri, Levrat et al. 2007), other studies of ATC have found normal levels of fibrinogen and other clotting proteases  ADDIN EN.CITE (Simmons, Collins et al. 1969; Brohi, Cohen et al. 2007; Brohi, Cohen et al. 2008). Thrombin generation, as measured by concentration of prothrombin fragments, rises with increasing injury severity and this is not reduced by either acidosis or hypothermia (Brohi, Cohen et al. 2008). Of the studies to measure platelets the largest found that only 3% of patients presented with low counts (<100,000 *106 L-1) and this was not an independent predictor of mortality (MacLeod, Lynn et al. 2003). The other two studies found median platelet counts greater than 100,000 *106 L-1 in coagulopathic and non-coagulopathic patient groups alike  ADDIN EN.CITE (Rugeri, Levrat et al. 2007; Brohi, Cohen et al. 2008). 









Fig. 1.12. Incidence of coagulopathy in subgroups according to injury severity (ISS, four groups) and i.v. ﬂuids administered during the pre-clinical phase of care 






Only one study has reported upon the association between acidosis and development of ATC (Simmons, Collins et al. 1969). 10% (20/208) of patients with a normal PT had a pH < 7.3 on admission and 21% (4/19) of patients with a prolonged PT had a pH < 7.3. Patient temperature has also been measured in only one study  ADDIN EN.CITE (Niles, McLaughlin et al. 2008). They found no association between hypothermia (T < 35C) and mortality and did not report any association with ATC.

1.4.7. 	The Protein C Pathway









Fig. 1.14. Indirect evidence for activation of protein C. A: Partial thromboplastin time is prolonged as protein C falls. Protein C in quartiles. *P = 0.001 compared with protein C 102%. B: Prothrombin time is prolonged as protein C falls. Protein C in 





Table 1.1. The Relationship of Low Protein C and High Thrombomodulin Levels to Clinical Outcomes.






Fig. 1.15. Schematic diagram of protein C activation. Protein C (PC) is activated by thrombin (IIa) bound to thrombomodulin (TM) located on the endothelial cell surface. EPCR localises protein C on the endothelial cell membrane and enhances the activation of protein C. Adapted from (Mosnier and Griffin 2006)

The extent of in vivo protein C activation is largely determined by the bioavailability of thrombin and protein C, and by the relative abundance of thrombomodulin and EPCR, co-expressed on a given cell surface. In this way thrombin generation and protein C activation are tightly correlated. The majority of aPC is likely formed within microvascular capillary beds; endothelial cells in these segments of the vascular tree express abundant levels of TM, whereas expression is much lower in the endothelium of larger arteries and veins (Weiler 2010). In addition to activating protein C the catalytic complex inhibits the procoagulant activity of thrombin. Relative to free thrombin, thrombin bound to thrombomodulin is inactivated much more rapidly by antithrombin and the protein C inhibitor, with an estimated half-life for inactivation of approximately 2 s (Rezaie, Cooper et al. 1995).

In general terms, aPC has both anticoagulant and anti-inflammatory functions. It degrades the active forms of coagulation factors V and VII (fVa and fVIIIa) by proteolysis, thereby limiting the extent of further thrombin generation. The non-enzymatic cofactor protein S, which forms a complex with aPC, enhances this process. Activated protein C also depletes plasminogen activator inhibitor 1 (PAI-1), thus reducing tissue type plasminogen activator (tPA) inhibition and accelerating the conversion of plasminogen to plasmin with subsequent enhancement of fibrinolysis (Rezaie 2001). This effect was also identified in trauma patients by Brohi et al, with increasing D-dimer and tPA concentrations together with reducing PAI-1 as protein C levels became exhausted (Brohi, Cohen et al. 2008). 

In addition to inactivating factors Va and VIIIa, aPC has been shown to have anti-inflammatory, anti-apoptotic, and anti-coagulant activity at the cellular level (Esmon 2003). The anti-inflammatory effects of aPC are primarily mediated through (EPCR dependent) activation of the G-protein coupled thrombin receptor, protease-activated receptor 1 (PAR-1). Direct activation of this receptor by thrombin diminishes cell survival, elicits inﬂammatory changes, and disrupts the vascular endothelial barrier secondary to re-organisation of the cytoskeleton. However, proteolytic cleavage by the aPC-EPCR complex activates a different intracellular signaling pathway with subsequent cytoprotection and preservation of the vascular permeability. 

Depletion of protein C has been consistently documented in septic patients and administration of supplementary aPC is associated with improved survival in animal and human studies  ADDIN EN.CITE (Bernard, Vincent et al. 2001; Toltl, Swystun et al. 2008). Theoretically, activation of the protein C pathway in other conditions of systemic hypoperfusion could provide physiological benefits by inhibiting intravascular coagulation, maintaining flow in poorly perfused vascular beds and protecting cells from ischaemia-reperfusion injury. Indeed, this response might be expected in trauma patients who have increased circulating thrombin (from tissue injury and/or systemic inflammation). However, in a patient with uncontrolled bleeding it may be that this benefit is outweighed by a potential increase in blood loss from systemic anti-coagulation.






Trauma is a leading cause of death worldwide. Approximately 40% of trauma deaths occur through haemorrhage and this is the leading cause of preventable death. Whilst bleeding from some injuries is amenable to surgical control, much relies on the intrinsic haemostatic capacity of the individual patient. Impairments of haemostasis after trauma increase blood loss and are associated with increased transfusion requirements, worse organ injury and higher mortality. 

Trauma induced coagulopathy can develop at any stage after injury secondary to loss, dilution or dysfunction of the coagulation proteases. Loss is explained as being due to bleeding or consumption, dilution from fluid administration and massive transfusion, while protease dysfunction results from hypothermia and the effect of acidosis on enzyme function.

Acute traumatic coagulopathy is an endogenous impairment of haemostasis that occurs early after injury. Most commonly it is diagnosed by a 50% prolongation of the PT or aPTT time on admission to the emergency room. However, this threshold is arbitrary and offers little prognostic value. A robust and clinically relevant definition of ATC is required to improve our recognition and management of this condition. 






































































To date, identification of ATC has been based on traditional transfusion triggers recommended by generic massive transfusion guidelines  ADDIN EN.CITE (Pathologists 1994; O'Shaughnessy, Atterbury et al. 2004; Therapies 2006). Most commonly these are a 50% prolongation of the PT or aPTT. However, this threshold is arbitrary and its clinical significance in terms of actual clinical outcomes is unknown. Patients with less severe ATC may also have worse outcomes and potentially benefit from therapeutic intervention. The reported prevalence of ATC varies widely and will depend in part on a robust definition.    








With local ethical approvals, five established trauma registries (The Royal London Hospital, The Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie/German Trauma Society (TR-DGU), Academic Medical Center Amsterdam, Ullevål University Hospital Oslo and San Francisco General Hospital) were retrospectively reviewed for trauma patients admitted between January and December 2007. There were some differences in patient inclusion criteria for the datasets. The Oslo dataset included all trauma patients, London excluded patients discharged from the emergency department, the San Francisco dataset only included patients with higher-level trauma team activation and the German registry only included patients with an ISS ≥9. Where information was available, patients taking oral anticoagulants, with pre-existing liver disease or who had arrived as a secondary transfer were excluded from the analysis.
Data were collected on patient demographics, mechanism of injury, transfer to hospital time, ISS, admission BD, admission PT or Quick’s Values (QV) or INR, PRBC and FFP units received in the first 24 hours of admission, and hospital mortality. 




Data analysis was performed using Microsoft Excel software and GraphPad Prism 5 statistical package. Parametric data are expressed as mean +/- standard error with multigroup analysis by one-way ANOVA and Bonferroni’s multiple comparison tests. Non-parametric data are expressed as median and IQR with two-group analysis performed by Fishers exact test or Chi-square (2), as appropriate. Non-parametric multigroup analysis was performed using Kruskal-Wallis and Dunn’s multiple comparison tests. Multiple logistic regression was performed to determine the risk of death for ISS, BD and PTr. Multiple linear regression was performed to determine the independent influence of ISS and BD on admission PTr.

2.5.1.    Results	





Age	39 (25-54)	33 (24-39)	37 (24-52)	38 (22-55)	38 (25-54)	41 (27-58)
Male (%)	2716 (75%)	499 (79%)	347 (73%)	460 (75%)	185 (78%)	1225 (73%)
 						
Time to ED	60 (42-83)	62 (48 - 81)	N/A	62 (32-108)	27 (21-34)	63 (48-85)
 						
ISS	22 (10-33)	17 (9 - 29)	9 (4-16.5)	14 (5-26)	21 (13-30)	27 (18-38)
ISS > 15	2425 (67%)	356 (57%)	146 (31%)	300 (49%)	168 (71%)	1455 (86%)
Blunt Injury	3276 (90%)	510 (81%)	448 (94%)	566 (92%)	163 (69%)	1589 (94%)
 						
BD (mmol/l)	2.7 (0.6-5.8)	2.7 (0.6 - 6.2)	1.3 (-0.4-3.4)	1.4 (-0.6-3.7)	5.6 (3.1-9.3)	3.4 (1.2-6.3)
BD  > 6 mmol/l	871 (24%)	170 (27%)	47 (10%)	81 (13%)	111 (47%)	462 (27%)
 						
PTr	1.1 (1.1-1.4)	1.0 (1.0 - 1.1)	1.1 (1.1-1.2)	1.1 (1.1-1.3)	1.0 (1.0-1.1)	1.3 (1.1-1.8)
PTr > 1.2	1323 (36%)	84 (13%)	86 (18%)	174 (28%)	31 (13%)	948 (56%)
PTr > 1.5	700 (19%)	33 (5%)	21 (4%)	57 (9%)	9 (0%)	580 (34%)

Table 2.1. Clinical characteristics of trauma patients
ED, Emergency Department Values are number (%) or median (inter-quartile range).

2.5.2. 	Relationship between admission coagulopathy and outcomes





Fig. 2.1. Relationship between admission PTr and hospital mortality. *P < 0.001 compared with PTr = 1.





Variable	OR of death	p	Standardised Coefficient	p
ISS	1.055	< 0.001	0.467	< 0.001
BD	1.111	< 0.001	0.295	< 0.001
PT Ratio(c)	1.307	< 0.001	0.195	< 0.001

Table 2.2. Odds ratios and standardised coefficients for death. OR, odds ratio






Fig. 2.2. Relationships between admission PTr and blood products transfused. *P < 0.001 compared with PTr = 1. +P < 0.001 compared with PTr = 1. 

2.5.3. 	Prevalence of ATC

Figure 2.3 shows the prevalence of abnormal PT ratios in the study cohort. 36.2% had a PTr > 1.2 compared to 19.2% with a PTr > 1.5. The classical definition of coagulopathy as a PT prolonged over 1.5-times normal would miss 17% of this trauma cohort with a PT ratio of 1.3-1.5, who have significantly increased transfusion requirements (four times more units of PRBCs and FFP) and three-fold higher mortality than patients with a normal PTr.


Fig. 2.3. The prevalence of prothrombin ratios in the emergency department.

2.5.4. 	Coagulation responses to trauma and shock





Fig. 2.4. Associations between injury, shock and coagulopathy.  A. Increasing prevalence of ATC with increasing severity of injury. B. Increasing prevalence of ATC with increasing severity of shock.

The PTr showed a strong correlation with both injury severity (ISS: r = 0.38, p < 0.001) and hypoperfusion (BD: r = 0.31, p < 0.001). In a multiple linear regression model these variables had similar standardised coefficients for predicting PTr (ISS: 0.162 vs. BD: 0.208, p = ns). Figure 2.5a shows a multivariate plot of PT ratio against both ISS and BD. In the absence of hypoperfusion the median admission PTr did not exceed 1.2, regardless of the injury severity. Similarly, without a significant injury load (ISS > 16) the median PTr did not exceed 1.2, regardless of the severity of hypoperfusion. With increasing combined injury severity and hypoperfusion there was a stepwise increase in the PTr. The worst coagulopathies were seen in patients admitted with the combination of most severe injuries and highest base deficits (ISS > 35 and BD > 12, median PT ratio = 2.0). A similar pattern of co-association is seen when mortality is plotted as the dependent variable (Fig. 2.5b). Numbers of patients, median PTr, mortality and the prevalence of ATC in each category are displayed in table 2.3.


	ISS < 16	ISS 16 – 25	ISS 26 – 35	ISS > 35
	N	PTr	Died	ATC	N	PTr	Died	ATC	N	PTr	Died	ATC	N	PTr	Died	ATC
BD ≤ 0	386	1.1	1%	10%	160	1.1	4%	23%	134	1.1	15%	29%	45	1.2	20%	47%
BD 0.1 - 6	706	1.1	2%	15%	480	1.1	4%	27%	537	1.2	25%	45%	325	1.4	26%	66%
BD 6.1 - 12	93	1.1	4%	30%	119	1.2	9%	48%	206	1.3	29%	48%	205	1.5	49%	68%
BD > 12	34	1.2	21%	44%	33	1.5	40%	52%	75	1.5	60%	68%	108	2	70%	80%

Table 2.3. The Relationship between Injury Severity and Shock




Fig. 2.5. The Relationship between Injury Severity and Shock
A. Median prothrombin ratios of patients grouped acording to ISS and BD. *P < 0.0001 compared with ISS < 16, BD ≤ 0. B. Mortality of patients grouped according to ISS and BD. *P < 0.001 compared with ISS < 16, BD ≤ 0.
2.6. 	Discussion

ATC has variable definitions in the literature that are based on relatively weak evidence from studies in non-trauma patient populations. Some trauma studies have defined coagulopathy as clotting times outside the normal range for healthy subjects (MacLeod, Lynn et al. 2003). A few have included a deficiency of platelets as an alternate criterion  ADDIN EN.CITE (Maegele, Lefering et al. 2007). Most have used an INR greater than 1.5, adopted from generic international guidelines for initiating FFP administration  ADDIN EN.CITE (Pathologists 1994; O'Shaughnessy, Atterbury et al. 2004; Therapies 2006). This threshold was derived from correlations between clotting times and the incidence of dilutional microvascular bleeding in patients undergoing massive transfusion  ADDIN EN.CITE (Counts, Haisch et al. 1979; Ciavarella, Reed et al. 1987; Murray, Olson et al. 1988; Murray, Pennell et al. 1995). However, the pathophysiology of ATC differs substantially from dilution-induced coagulopathy and this may be reflected in haemostatic parameters used to monitor it. 
This study has shown that ATC is associated with worse outcomes at a PT ratio >1.2. This threshold is lower than previous definitions of ATC and reveals the clinical implications of more subtle early abnormalities of coagulation. It identifies an additional 17% of all trauma patients who are at risk of worse outcomes and may benefit from haemostatic therapies. 
Most observational studies have treated ATC as a binary variable with respect to outcomes. However, in this study we see that as the PTr increases beyond 1.2 there is a continuous rise in all cause mortality and transfusion requirements. A positive dose-response relationship between coagulation parameters and mortality has been identified previously (Hess, Lindell et al. 2009). They were able to discriminate the risk of mortality using INR only for patients with moderate and severe injuries. In another small single centre military study, trauma combat casualties requiring transfusion had an increasing probability of death with INRs > 1.5  ADDIN EN.CITE (Niles, McLaughlin et al. 2008). Assimilating coagulation and mortality data from multiple institutions in this study enabled the capture of a larger trauma cohort and improved the resolution of this relationship. When using standard laboratory tests of coagulation, ATC should be defined as an admission PTr > 1.2. Worse outcomes should be expected with increasing prolongations of the PTr above this threshold. 
The prevalence and severity of ATC co-associates with both the severity of injury and depth of shock sustained by trauma patients. A positive correlation between injury severity and coagulopathy is consistent with all previous studies of ATC  ADDIN EN.CITE (Brohi, Singh et al. 2003; MacLeod, Lynn et al. 2003; Brohi, Cohen et al. 2007; Maegele, Lefering et al. 2007; Brohi, Cohen et al. 2008). A potential association with shock was identified in a prospective study of 208 patients in which increasing systemic hypoperfusion was associated with a progressive prolongation of the PT and aPTT (Brohi, Cohen et al. 2007). This mirrored findings in a military study conducted over 30 years earlier during the Vietnam War (Simmons, Collins et al. 1969). 
Given that haemorrhage often co-exists with severe injury, shock could confound the coagulation effects of tissue injury and be the primary driver of ATC. However, there are three findings of this study that indicate this is probably not the case. Firstly, the prevalence of ATC in severely injured but non-shocked (ISS > 35, BD < 0: 47%) patients is almost exactly the same as in those with ‘minor injuries’ and severe shock (ISS < 16, BD > 12: 44%). Secondly, the median PTr of these two groups is the same. Thirdly, the magnitude of independent effect of ISS or BD on PTr is strikingly similar (correlation coefficients of 0.162 and 0.208, respectively). Determining whether shock can induce ATC in the complete absence of tissue injury is not possible in this study because ISS is a non-linear composite score that reflects the risk of mortality from injury, rather than the volume of injured tissue per se. Similarly, whether there is any synergism between tissue injury and shock cannot be determined because the PT is a non-linear scale with respect to activity of coagulation factors. However, for a given severity of injury, there is a progressive prolongation of the PTr with increasing degrees of shock, and vice-versa. The worst coagulopathies should be anticipated in patients who arrive with a combination of severe injury and shock, as evidenced by an abnormal base deficit. 
A significant correlation between injury severity, shock and ATC is consistent with an endogenous pathophysiology. The amount of pre-hospital fluid received and the admission body temperature were not included in all datasets. However given the short transport times and the pre-hospital care practices (low volume crystalloid fluid resuscitation, active environmental warming) it is unlikely that pre-hospital dilution and hypothermia were severe enough to make a significant contribution to the coagulopathy. An elevated base deficit is indicative of metabolic acidosis and the degree to which acid per se contributed to ATC, independent of associated hypoperfusion related pathologies (eg. hypoxia, inflammation, complement activation), is difficult to differentiate. 
An endogenous mechanism for the pathogenesis of ATC is consistent with a hypothesis of systemic activation of the Protein C pathway. Thrombin is produced by local activation of coagulation following tissue damage, which in turn would lead to fibrin generation. However, if hypoperfusion caused an increase in thrombomodulin, this could switch thrombin to its anticoagulant and profibrinolytic function via the generation of aPC. In bleeding patients this may represent a harmful side effect of an organ protective anti-inflammatory response. It was not possible to measure individual coagulation factors or markers of systemic activation of coagulation and/or fibrinolysis. Therefore, from this data it is impossible to exclude a consumptive coagulopathy from either local and/or systemic activation of coagulation. Similarly, aPC has yet to be measured in human ATC and it is unclear whether this is the dominant mechanism for the coagulopathy. A logical next step would be to perform a prospective cohort study with detailed record of all major variables known to influence haemostasis after trauma. Ideally, this would commence at the injury scene and continue through resuscitation to recovery in order to evaluate the time course and importance of ATC within TIC. Analysis of individual pro- and anticoagulant components would indicate the likely interplay and relative importance of potential pathophysiologies.
There are several limitations to this study. It was retrospective and based on available registry data with differences in registry inclusion criteria between institutions. Full datasets were not available on a large number of patients, and it may be that base deficits and prothrombin times are only performed on more severely injured patients.  This may explain the high massive transfusion rate. Patient medication and pre-morbid coagulation status were not always known and these may be confounders, although the majority of trauma patients are young adults. The aPTT or other tests of haemostasis were also not available. 
Prothrombin ratios were calculated from recorded PT/QV/INR results, which may vary between institutions depending upon the test methods used. With the threshold for ATC reduced to a PTr of 1.2, there is now a narrow window between normal and abnormal PT readings, and the effects of differences in reagents may become more important. As much care as possible was taken in normalising these variables to PTr, and the ISIs for the reagents were similar across centres. However, definitions suitable for international research and clinical guidelines have to accept a degree of variability for the purposes of pragmatic utility.   


















































Trauma accounts for 9% of the world’s deaths and kills more people aged 1-44 than any other disease (Peden M 2002). Contemporary analyses show that haemorrhage contributes to half of these deaths and is the leading reversible cause  ADDIN EN.CITE (Tien, Spencer et al. 2007; Evans, van Wessem et al. 2010). In survivors, the incidence of sepsis and MOF correlate directly with the depth of initial haemorrhagic shock  ADDIN EN.CITE (Chaudry and Ayala 1993; Davis, Parks et al. 1996; Durham, Moran et al. 2003). Therefore, haemostasis is a clinical priority after trauma and has become a prime target for translational research. 

A new paradigm of transfusion practice has shown the potential to dramatically improve outcomes after injury. Damage control resuscitation, targeting a sub-physiological systolic pressure until surgical control of bleeding, is preferred to chasing ‘normal’ parameters. Early administration of plasma, fibrinogen and platelets in a balanced ratio to erythrocytes is associated with significantly lower morbidity and mortality  ADDIN EN.CITE (Stansbury, Dutton et al. 2009). A large randomized controlled trial of anti-fibrinolytic therapy with Tranxemic Acid has demonstrated a 9% relative risk reduction of death  ADDIN EN.CITE (Shakur, Roberts et al. 2010). 

Robust and clinically relevant animal models of TIC are required to support this evolution of transfusion protocol. Retrospective human studies are subject to the quality of data collection, confounding and survivor bias. In-vitro studies of pathophysiology and therapeutic efficacy neglect the powerful role of the endothelium in orchestrating coagulation and other interconnected systems. Performing prospective clinical trials to determine the optimal combination of these haemostatic products is expensive and logistically difficult. Animal models are needed to identify the most promising therapies and elucidate their mechanism of action. 

Conventional perception of TIC as an iatrogenic process inspired laboratory models investigating haemodilution, hypothermia and acidosis as separate pathological initiators. However, the recognition of an endogenous acute traumatic coagulopathy, initiated by injury and systemic hypoperfusion, has changed our understanding of the aetiology and chronology of TIC (fig. 1). Animal models of the condition need to be revised accordingly to accurately reflect the natural clinical trajectory of trauma. An ideal model should feature appropriate patterns of initiating injury, secondary uncontrolled hemorrhage, subsequent development of spontaneous hypothermia and acidosis, contemporary resuscitation maneuvers and coagulopathy measurable by both laboratory and clinical methods. 














The search process retrieved 320 abstracts, 27 of which were relevant to this review. A further 15 articles were identified by the authors. The main aim of 26 studies was to test a therapeutic and these were mostly unblinded randomised controlled trials. The other 16 were conducted to investigate the pathophysiology of TIC. Many of the studies were performed by the same authors and utilised previously published models with minor variations in the protocol. Table 1 summarises each publication that was considered to demonstrate a distinct model of TIC. 

Author	Year	Species	Cause & Chronology of Coagulopathy	Diagnostic Tests	Therapeutic
Reed et al.	1992	Rat	Hypothermia	PT/aPTT/TT	
Martini et al., 	2007	Pig	Hypothermia	TEG/TGA	
Schwaitzberg et al.	2004	Rabbit	HypothermiaTrauma/Hemorrhage	Blood loss	SyvekPatch
Martini et al.	2008	Pig	HypothermiaHemorrhageDilution	PT/aPTT/TEG/TGAFib/Platelets	
Iwamoto et al.	2010	Rat	Hypothermia Hemorrhage Dilution	Sonoclot	
Martini et al.	2007	Pig	Acidosis	PT/aPTT/TEGFib/Platelets	THAM
Martini et al.	2005	Pig	AcidosisHypothermiaTrauma/Hemorrhage	PT/aPTT/TEGFib/PlateletsBlood loss	
Hardaway et al.	1990	Pig	Trauma	PT/aPTT/CTFib/Platelets	Urokinase/tPa
Gierer et al.	2008	Rat	TraumaEndotoxaemia	PT/aPTT	




Martini et al.	2006	Pig	HemorrhageDilution	PT/aPTT/TEGFib/Platelets	Lactated Ringers
Kiraly et al.	2006	Pig	Trauma/HemorrhageDilution	PT/aPTT/TEGFib/PlateletsBlood loss	Normal salineLactated Ringers
Hewson et al. 	1991	Rabbit	DilutionHemorrhage	PT/aPTTClotting factors	
Fries et al.	2006	Pig	DilutionTrauma/Hemorrhage	PT/aPTT/TEGFib/PlateletsBlood loss	FibrinogenPCC
Pragst et al.	2010	Rabbit	DilutionTrauma/Hemorrhage	PT/TGAFib/PlateletsBlood loss	PCCrFVIIa
Klemcke et al.	2005	Pig	DilutionHypothermiaTrauma/Hemorrhage	PT/aPTT/TEGFib/PlateletsBlood loss	rFVIIa
Kheirabadi et al.	2008	Rabbit	DilutionHypothermiaTrauma/Hemorrhage	PT/aPTT/TEGFib/PlateletsBlood loss	AlbuminHextendDextran 70
Dickneite et al.	2010	Pig	DilutionHypothermiaTrauma/Hemorrhage	PT/apt/TGAFib/PlateletsBlood loss	PPCrFVIIa
Alam et al.	2009	Pig	Trauma/HemorrhageDilutionAcidosisHypothermia	PT/aPTT/TEGFib/PlateletsBlood loss	FWBHextendPRBCFFP





3.3.2. 	Choice of Species





The tests used to assess haemostatic competency varied both in their number and complexity. Routine tests of coagulation (PT/aPTT) were commonplace and the only measure used in 4 of the 5 rodent models. Although test protocols were occasionally modified (eg. plasma sample volume or temperature), the thromboplastin initiators were all purchased commercially and not species specific. Larger animal models featured more comprehensive coagulation analysis and invariably reported fibrinogen concentration and platelet number, but not function. Nevertheless, only two studies, one performed on sheep and one on rabbits, assayed the activity of individual coagulation proteases. Viscoelastic measures of whole blood clotting, predominantly TEG in North American papers and ROTEM in European, have been used with increasing frequency. Occasionally this has led to inconsistencies between the reported direction and magnitude of coagulopathy when measured with different tests. For example, a grade V liver injury in pigs followed by resuscitation with normal saline or lactated Ringer’s produced a prolongation of the PT and aPTT, but also a shortening of initial clotting times (R values) and increased clotting rapidity ( angle) on TEG  ADDIN EN.CITE (Kiraly, Differding et al. 2006). Many studies neutralised this issue by including a measure of clinical coagulopathy, such as bleeding time or volume of blood lost after hepatic/splenic injury. 

3.3.4. 	Pathophysiology: Isolated Trauma or Shock

In general, studies of pathophysiology employed a single modality to induce coagulopathy and tests of therapeutics were more complex. Isolated trauma has been inflicted by striking the thigh  ADDIN EN.CITE (Hardaway, Williams et al. 1990; Gierer, Hoffmann et al. 2008), lung contusion (Giannoudis, van Griensven et al. 2008) and laparotomy (Chesebro, Rahn et al. 2009). They caused an acute reduction in platelets  ADDIN EN.CITE (Hardaway, Williams et al. 1990), fibrinogen (Giannoudis, van Griensven et al. 2008), factor V (Giannoudis, van Griensven et al. 2008) and antithrombin III (Giannoudis, van Griensven et al. 2008), but no discernible effect on PT or aPTT. Similarly, shock alone, produced by pressure-controlled haemorrhage from indwelling catheters, did not significantly prolong routine tests of coagulation. One mechanism proposed for the activation of coagulation after trauma is tissue factor release from injured areas. This has been simulated in rats without inflicting physical injury by the intravenous administration of tissue factor. This induced a reduction in platelets and fibrinogen, and elevated D-dimer and thrombin-antithrombin complexes was cited as evidence of a consumptive coagulopathy. However, little fibrin deposition was recorded and results of global screening tests of coagulation were not reported.  

3.3.5. 	Combined Trauma & Shock (ATC)





Fixed volume haemorrhage in rabbits (25 ml/kg)(Nielsen 2001) or pigs (35% estimated circulating volume)(Martini, Chinkes et al. 2006) followed by fluid resuscitation (25 ml/kg Hextend and Ringers lactate/normal saline at 3 times the volume of shed blood, respectively) produces a reduction in platelets (Nielsen 2001), fibrinogen (Martini, Chinkes et al. 2006), a shortening of TEG R value  ADDIN EN.CITE (Nielsen 2001; Martini, Chinkes et al. 2006) and reduced maximum amplitude of clot strength  ADDIN EN.CITE (Fries, Haas et al. 2006). Similar results are found when the haemorrhage is uncontrolled such as after standardized grade V liver injury, produced by a purpose-designed clamp with disruption of a central hepatic vein, in pigs  ADDIN EN.CITE (Kiraly, Differding et al. 2006). Of note, resuscitation with lactated Ringer’s attenuated these changes compared with normal saline. 

3.3.7. 	Hypothermia & Acidosis







Most multi-modal studies of TIC have involved significant haemodilution prior to the traumatic and/or haemorrhagic insult. With or without concomitant hypothermia, up to 70% of the estimated circulating volume of pigs and rabbits has been exchanged with a variety of fluid products that are devoid of coagulation factors. After blood sampling for laboratory tests of coagulation function the effect on clinical haemostasis and survival is assessed by inflicting a liver injury  ADDIN EN.CITE (Klemcke, Delgado et al. 2005; Fries, Haas et al. 2006), kidney injury (Pragst, Kaspereit et al. 2010) or splenic injury  ADDIN EN.CITE (Kheirabadi, Crissey et al. 2008; Dickneite, Dörr et al. 2010). 





This review identifies a general lack of animal models capable of accurately supporting our evolving clinical understanding of TIC. There are few models that are methodologically distinct and none of them simulate all components of TIC in correct chronological order. Aetiologically, ATC is initiated by tissue injury and haemorrhagic shock. Innate inflammatory networks are activated and imbalance develops between pro- and anticoagulant pathways. All subsequent derangements (hypothermia, acidosis and iatrogenic haemodilution) occur in a haemostatic system already in disequilibrium. The value of studies evaluating pathophysiology or therapeutic efficacy in models without initiating tissue injury and/or haemorrhagic shock is limited. 

3.4.2. 	Choice of Species













Systemic hypoperfusion secondary to uncontrolled haemorrhage is a principle driver of human ATC. However, most animal models utilised a fixed pressure or volume bleed from indwelling vascular catheters to prime the coagulation system for resuscitation  ADDIN EN.CITE (Hewson, Prodger et al. 1991; Reed, Johnson et al. 1992; Nielsen 2001; Martini 2007; Giannoudis, van Griensven et al. 2008; Chesebro, Rahn et al. 2009). Other models that have featured an uncontrolled haemorrhage have used it only as a measure of clinical coagulopathy, rather than to induce coagulopathy  ADDIN EN.CITE (Klemcke, Delgado et al. 2005; Fries, Haas et al. 2006; Kheirabadi, Crissey et al. 2008; Alam, Bice et al. 2009; Dickneite, Dörr et al. 2010; Pragst, Kaspereit et al. 2010). Further, the natural chronology of TIC was often artificially reversed with haemodilution and hypothermia preceding the trauma and bleed  ADDIN EN.CITE (Hewson, Prodger et al. 1991; Klemcke, Delgado et al. 2005; Fries, Haas et al. 2006; Kheirabadi, Crissey et al. 2008; Pragst, Kaspereit et al. 2010). The effects of haemostatic products and resuscitation fluids are likely to depend upon the state of the coagulation system at the time of administration. Therefore, it is vital that future models designed for testing therapeutics feature some degree of uncontrolled haemorrhage, preferably to induce ATC, with haemodilution occurring during or after the bleed. 


3.4.6. 	Hypothermia & Acidosis








































Injury and systemic hypoperfusion have been identified as prime aetiological factors of ATC. Clinical studies have confirmed a positive correlation between ISS and the degree of ATC  ADDIN EN.CITE (Brohi, Singh et al. 2003; Maegele, Lefering et al. 2007). Hypoperfusion, probably occurring through haemorrhagic shock, appears to be requisite (Brohi, Cohen et al. 2007). However, it is not known if a threshold level of hypoperfusion must be reached and/or whether this relationship is dose-dependent. Furthermore, because ISS is a composite score (of injury, blood loss and risk of death), there is no way to definitively separate these two variables and assess their relative contributions in human studies. 

Conventional mediators of TIC do not appear to be the main drivers of ATC. It develops rapidly, before spontaneous hypothermia is likely to have developed to any significant degree and it can occur in the absence of crystalloid haemodilution  ADDIN EN.CITE (Brohi, Singh et al. 2003; Maegele, Lefering et al. 2007). Reports of coagulation factor consumption from human studies are inconsistent, but depletion of major elements does not appear to occur to a level compatible with significant coagulopathy. This implies that it is an endogenous process. Indeed, it has been characterised as a condition of systemic anticoagulation and hyperfibrinolysis  ADDIN EN.CITE (Brohi, Cohen et al. 2007; Brohi, Cohen et al. 2008).

These observational studies are useful for characterising early haemostatic responses to injury within a target population. Associations can be made between changes in physiology, coagulation factors and the development of coagulopathy. However, proof of causal involvement of a putative factor is not possible, as associated variables cannot be controlled.

Ex vivo tests of normal or coagulopathic human blood offer the ability to investigate some individual variables, such as the effect of temperature changes (albeit ‘induced’ rather than ‘spontaneous’). Similarly, spiking tests have been employed extensively to characterise dilutional effects of different resuscitation products. Unfortunately, by their nature, these experiments are performed with laboratory equipment that do not offer adaptive physiological responses to deliberate shifts of haemostatic function. Perhaps most important among these is the powerful effect of the endothelium. Computer simulations have also been used to demonstrate dilutional effects of different resuscitation paradigms. However, they are constructed using our limited knowledge of the haemostatic system, which restricts their validity. 












Male Wistar rats (Charles River Ltd, Margate, UK) weighing 230 g to 360 g were assigned to sham control (S), trauma (T), haemorrhagic shock (H) or trauma and haemorrhagic shock groups (TH). They received a standard diet and water ad libitum, and were cared for in accordance with the UK Home Office Guidance in the Operation of the Animals (Scientific Procedures) Act 1986. General anesthesia was induced and maintained with intra-peritoneal sodium thiopentone (Intraval Sodium, 120 mg kg)1) and body temperature was maintained at 37 ± 1 °C. A tracheotomy was performed and a small section of polyethylene tube (Internal Diameter 1.67 mm; Portex, Hythe, UK) inserted to aid respiration. 

Sham control animals (S) were anaesthetised, tracheotomised and monitored. Rats in trauma groups (T and TH) received a 6 cm paramedian laparotomy, closed in one layer with 7 mm surgical clips (Harvard Apparatus, Tonbridge, UK) and bilateral mid-shaft closed tibia and fibula fractures, produced using 3-point distraction with a pair of chest drain clamps. The experimental period commenced immediately after traumatic injury (or 7 min after completion of carotid catheterisation in (S) or (H) animals - the mean time taken to complete traumatisation).

4.3.2. Study 1. Characterisation of coagulation responses in a fixed pressure haemorrhage model of ATC

The left carotid artery of all animals was catheterised with polyethylene tubing (Internal Diameter 0.58mm, Portex) connected to a pressure transducer (Capto SP 844, AD instruments, Chalgrove, UK) and syringe pump (PHD 22/2000, Harvard Apparatus) by means of a 3-way connector. Initial blood pressure was measured immediately after catheter insertion. Normal saline was continuously infused at a rate of 200 l per hour with supplementary manual flushes in order to maintain patency of the carotid catheter. No heparin or other anticoagulant was used or administered. A starting blood pressure was recorded and 100 l of blood was aspirated from all animals at the commencement of the experimental period for arterial blood gas analysis (ABL 77, Radiometer, Crawley, UK). Animals in haemorrhagic shock groups (H or TH) were bled to a MAP of 40 – 50 mmHg over a period of 10 minutes and this pressure was maintained by further withdrawals as necessary during the experimental period. In order to investigate the effect of increased shock a further group of (TH) rats were traumatised and haemorrhaged to a MAP of 30 – 40mmHg.

4.3.3. Study 2. Characterisation of coagulation in a fixed volume haemorrhage model of ATC

Blood withdrawal and terminal sampling was performed by intermittent catheterisation of the left carotid artery with polyethylene tubing  (Internal Diameter 0.58mm, Portex) connected to a 5ml syringe. 50%, 20%, 10%, 10% and 10% of total haemorrhage volume was withdrawn at experimental time points 0, 10, 20, 30 and 40 minutes, respectively. Between withdrawals the vessel was clamped and catheters were removed. No fluid was administered.  

One group of (H) rats had a total of 40% of their estimated circulating volume withdrawn and another group had 45% withdrawn. Similarly, one group of (TH) rats had 30% of their estimated circulating volume withdraw and another had 35% withdrawn. Previous experiments indicated lower limb fracture would lead to the loss of approximately 10% of estimated circulating volume. Therefore, this protocol could be expected to produce comparable volumes of blood loss in (H) and (TH) groups.
The left carotid artery of (S) and (T) group animals were clamped throughout the experimental period until catheterisation for terminal blood sampling.

4.3.4. Terminal blood sampling and coagulation function analysis

After a 70 min experimental period, 0.5 ml of blood was aspirated from the carotid catheter and discarded. Next, 100 µl was aspirated into a heparin-lined syringe for arterial blood gas analysis. A further 2 ml was aspirated into a 5 ml syringe pre-filled with 200 µL of 3.2% sodium citrate (Sigma-Aldrich, Gillingham, UK). Lactate measurement (Accutrend, Roche, Welwyn Garden City, UK) was performed with 20 µl of this sample and the remainder was centrifuged at 3500 g for 15 min at room temperature. Plasma supernatant was immediately snap frozen in liquid nitrogen and stored at -80 °C. All rats (n = 10 per group) survived to the end of the experimental period and were included for data analysis. Animals were subsequently euthanised by excision of their heart. 

Coagulation function tests were performed within three months (after thawing plasma samples for 5 minutes in a water bath at 37C) on a single channel thrombotrack coagulometer (Axis-Shield, Kimbolton, UK), using modified sample volumes. PT was measured by incubating 100 µl of Neoplastine CI reagent (Stago, Reading, UK) for 3 min followed by the addition of 50 µl of thawed plasma. APTT was performed by incubating 50 µl of Automate PTT reagent (Stago) with 50 µl of thawed plasma for 3 min followed by addition of 50 µl of 0.025 mmol calcium chloride.

For study 2, the activity of coagulation factors II, VII, VIII, X, Antithrombin, Protein C (Hyphen BioMed, Neuville-sur-Oise, France) and Tissue Factor Pathway Inhibitor (TFPI) (American Diagnostica, Stamford, USA) were measured by chromogenic assay, according to manufacturers instructions. Factor V activity was measured by coagulometric assay (Hyphen Biomed), according to manufacturers instructions. Fibrinogen and PAI-1 were measured by rat species specific enzyme linked immunosorbent assay (ELISA)  (Innovative Research, Michigan, USA) according to manufacturers instructions. The same assays were performed on pooled normal rat plasma (Innovative Research) for comparison.

4.3.5. Study 3. The coagulation function effects of ex-vivo haemodilution

10 male Wistar rats weighing 250 - 300 g were anaesthetised with intra-peritoneal sodium thiopentone (Intraval Sodium, 120 mg kg/1) and body temperature was maintained at 37 ± 1 °C. A tracheotomy was performed and a small section of polyethylene tube (Internal Diameter 1.67 mm; Portex, Hythe, UK) inserted to aid respiration. 10 minutes after surgery, laparotomy was performed and 5 ml of venous blood was aspirated from the inferior vena cava into a syringe pre-fillled with 0.5 ml of sodium citrate (3.2%, Sigma-Aldrich). Animals were then euthanised. 

The anti-coagulated whole blood was divided into 500 l aliquots and diluted by addition of normal saline at room temperature (50 l to aliquot 1, 100 l to aliquot 2, 150 l to aliquot 3, et cetera). This produced samples diluted by 9.1% (50/550 l), 16.7% (100/600 l), 23.1% (150/650 l) et cetera. These aliquots were centrifuged at 3500 g for 15 min at room temperature. Plasma supernatant was immediately snap frozen in liquid nitrogen and stored at -80 °C. PT and aPTT were measured within three months using the methods described for studies 1 and 2.

4.3.6. Study 4. The coagulation function effects of ex vivo acidosis











4.5.1. Study 1. Fixed pressure haemorrhage model of ATC

56 rats were utilised in this study. There were no deaths in either (S) or (T) groups.  There was 1 death before the end of the experimental period in (H), 1 in (TH40-50) and 4 in group (TH30-40). N = 10 rats survived to the end of the experimental period in all groups.

Mean blood pressures were similar between the groups after carotid catheterisation (S = 133.1 ± 11.8 mmHg, T = 131.8 ± 10.0 mmHg, H = 131.1 ± 18.8 mmHg, TH40-50 = 131.9 ± 6.2 mmHg, TH30-40 = 139.4 ± 14.4 mmHg; p > 0.05 between all groups) and at the start of the experimental period (S = 128.5 ± 14.1 mmHg, T = 111.5 ± 17.5 mmHg, H = 126.6 ± 18.5 mmHg, TH40-50 = 117.1 ±12.3 mmHg, TH30-40 = 122.4 ± 10.3 mmHg; p > 0.05 between all groups). The blood pressures of (S) and (T) groups had not changed significantly by the end of the experimental period (S = 125 ± 9.5 mmHg, T = 97 ± 15.1 mmHg, H = 45 ± 5.1 mmHg, TH40-50 = 45 ± 4.0 mmHg, TH30-40 = 33 ± 2.0).





Fig. 4.1a-d. Respiratory parameters of fixed pressure haemorrhage model. 4.1a. All rats had satisfactory and similar partial pressures of oxygen at commencement of the experimental period. 4.1b. At the end of the experimental period, rats subjected to haemorrhagic shock had developed significantly higher partial pressures of O2. *P < 0.05 compared with S. 4.1c. Ventilation was satisfactory for all rats at commencement of the experimental period. 4.1d. At the end of the experimental period, there was a trend towards increased ventilation for all rats subjected to haemorrhagic shock. This was statistically significant in groups with co-existent trauma. *P < 0.05 compared with S.

Mean haemoglobin at commencement of the experimental period was 13.2 ± 1.3 g/dl and was similar across all groups. Sham control animals displayed a statistically insignificant drop in haemoglobin and haematocrit during the experimental period from 13.1 ± 1.5 g/dl to 12.2 ± 1.7 g/dl (CI = -2.4 to 0.4) and from 40.6 ± 4.7% to 37.4 ± 5.5% (CI = -7.4 to 1.0), respectively. Traumatic injury resulted in a modest but statistically significant drop in haemoglobin and haematocrit from 12.9 ± 1.1 g/dl to 11.3 ± 1.3 g/dl (CI = -3 to -0.2) and from 40.0 ± 3.1% to 34.7 ± 3.7% (CI = -9.5 to -1.1), respectively. However, their mean end haemoglobin and haematocrit did not differ significantly from those of sham controls (Hb: T = 11.3 ±1.3 g/dl vs. S = 12.2 ± 1.7 g/dl, CI = -2.8 to 1.1). 





Fig. 4.2a-d. Haematological parameters of fixed pressure haemorrhage model. 4.2a & c. All rats had similar initial haemoglobin and haematocrit concentrations. 4.2b & d. Haemoglobin and haematocrits were significantly reduced by trauma and/or haemorrhagic shock. There is a trend towards greater anaemia in rats subjected to shock without trauma. +P < 0.05 compared with matched group at beginning of experimental period. *P < 0.05 compared with S at end of experimental period.





Fig. 4.3a-d. Fluid requirements and indices of shock severity for fixed pressure haemorrhage model. 4.3a. Rats in all groups received similar volumes of fluid to keep their carotid catheter patent. 4.3b. Haemorrhage produced a significant acidaemia in all 3 groups subjected to it. *P < 0.05 compared with S. +P < 0.0001 compared with TH(40-50). 4.3c. Haemorrhage produced a base deficit that was significantly increased by addition of traumatic injury. *P < 0.05 compared with S. +P < 0.0001 compared with H. 4.3d. Haemorrhage produced a significant lactataemia in all 3 groups subjected to it. *P < 0.05 compared with S.





Fig. 4.4a-b. Coagulation parameters of fixed pressure haemorrhage model. Trauma without haemorrhage had negligible effect on PT and aPTT times in this rat model. Haemorrhage alone caused a trend toward prolonged PT and aPTT times that did not reach statistical significance. Both trauma and haemorrhage were required to produce a statistically significant coagulopathy compared to sham controls. Combined with trauma, there was a trend towards increased prolongation of the aPTT with increasing the depth of shock. *P < 0.05 compared with S.

4.5.2. Study 2. Fixed volume haemorrhage model of ATC

76 rats were utilised in this study. There were no deaths in (S) or (T) groups. There were 2 and 5 deaths in groups of rats haemorrhaged 40% (H40%) and 45% (H45%) of their estimated circulating blood volume, respectively. There were 4 and 5 deaths in groups of rats traumatised and haemorrhaged 30% (TH30%) and 35% (TH35%) of their estimated circulating blood volume, respectively. N = 10 rats survived to the end of the experimental period in all groups. 





Fig. 4.5a-d. Respiratory parameters of fixed volume haemorrhage model. 4.5a. All rats had satisfactory and similar partial pressures of oxygen at commencement of the experimental period. 4.5b. There was a trend towards increased partial pressures of O2 at the end of the experimental period in all rats subjected to haemorrhagic shock. They were significantly higher in rats bled a greater volume (H45% and TH35%). *P < 0.05 compared with S.  4.5c. Ventilation was satisfactory for all rats at commencement of the experimental period. 4.5d. There was a trend towards increased ventilation for all rats subjected to haemorrhagic shock and this was statistically significant for groups H45%, TH30% and TH35%. *P < 0.05 compared with S.





Fig. 4.6a-d. Haematological parameters of fixed volume haemorrhage model. 4.6a & c. All rats had similar initial haemoglobin and haematocrit concentrations. 4.6b & d. Haemoglobin and haematocrits were significantly reduced by trauma and/or haemorrhagic shock. +P < 0.05 with matched group at beginning of experimental period. *P < 0.05 compared with S at the end of experimental period. All statistical comparisons between haemorrhaged groups were insignificant. 

The acid-base status and lactate concentration of rats in all groups were similar and within normal ranges at the beginning of the experimental period (data not shown). There was no significant change in the acid-base status or lactate concentrations during the experimental period in sham control or trauma alone groups (fig. 4.7a-c). Haemorrhage of 40% circulating blood volume in isolation, or 30% with associated traumatic injury, resulted in the development of a mild metabolic acidaemia and lactataemia. However, these groups were only statistically significantly different from sham controls in the base deficit parameter. Haemorrhage to 45% in isolation, or 35% with associated traumatic injury, produced a significant metabolic acidaemia (with partial respiratory compensation) and lactataemia compared to both sham controls and their lower haemorrhage volume counterparts (H40% and TH35%, respectively). However, there was no significant difference between these two groups in terms of either shock severity index.  
  

Fig. 4.7a-c. Indices of shock severity for fixed volume haemorrhage model. Trauma alone had an insignificant effect on acid-base parameters. Haemorrhaging 40% circulating blood volume, or 30% with associated trauma, produced a mild metabolic acidaemia and lactataemia. Haemorrhaging 45% circulating blood volume, or 35% associated with trauma, produced acidaemia and lactataemia significantly greater than S, H40 or TH30. *P < 0.05 vs. S. +P < 0.05 vs. H40%. #P < 0.05 vs. TH30%.

At the end of the experimental period, rats in the sham control group had a mean PT of 17.0 ± 0.7s and mean aPTT of 16.3 ± 2.7s (fig. 4.8a-b). Traumatic injury alone had negligible effect on these coagulation parameters (PT = 17.6 ± 1.2 s, CI = -1.5 to 2.7; aPTT = 17.8 ± 1.9 s, CI = -4.0 to 7.1). Similarly, compared with sham controls, there was no significant effect on coagulation parameters of haemorrhaging 40% of circulating blood volume, or 30% in association with traumatic injury (PT: H40% = 18.0 ± 0.9 s, CI = -1.1 to 3.0; TH30% = 18.8 ± 1.0 s, CI = -0.3 to 3.9. aPTT: H40% = 15.7 ± 3.2s, CI = -6.1 to 5.0; TH30% = 17.9 ± 2.7s, CI = 4.0 to 7.2). However, withdrawal of 45% of circulating volume, or 35% with traumatic injury, caused a significant prolongation of both the PT and aPTT with respect to sham controls (PT: H45% = 22.4 ± 2.7 s, CI  = 3.2 to 7.4; TH35%  = 21.9 ± 1.6 s, CI = 2.6 to 6.9. aPTT: H45% = 27.3 ± 7.0 s, CI = 5.5 to 16.6; TH35% = 27.0 ± 4.6 s, CI = 5.2 to 16.3). There was no significant difference in the effect on coagulation parameters between these two groups. 


Fig. 4.8a-b. Coagulation parameters of fixed volume haemorrhage model. Haemorrhaging 45% circulating volume, or 35% with traumatic injury, caused a significant prolongation of both the PT and aPTT. *P < 0.05 vs. S.

XY scatter plot of lactate and coagulation data from all 60 rats combined demonstrates a significant correlation between the depth of systemic hypoperfusion and coagulopathy (fig. 4.9a-b). This correlation is notably stronger for PT (r2 = 0.54) than for aPTT (r2 = 0.21).


Fig. 4.9a-b. Correlation between systemic hypoperfusion and coagulopathy. 4.9a. PT. 4.9b. aPTT. No animals with a lactate below 4 mmol/l had prolongations of their PT or aPTT greater than 1.2 times normal (17.0 s).

Haemorrhage, with or without traumatic injury and in the absence of exogenous fluid administration had the general effect of producing a global reduction in the potential activity of circulating procoagulant plasma proteins (fig. 4.10a-f). This appears to be dose-dependent with a consistent trend towards greater depletion in groups H45% and TH35% than in H40% and TH30%, respectively. This trend was statistically significant for factors II (TH35% = 59 ± 2% vs. TH30% = 80 ± 2%, CI = 7 – 34%), V (H45% = 58 ± 6% vs. H40% = 83% ± 3%, CI = 7 – 43%), VIII (TH35% = 45 ± 7% vs. TH30% = 75 ± 2%, CI = 11 – 49%) and X (TH35% = 41 ± 3% vs. TH30% = 70 ± 5%, CI = 9 – 49%).  Animals subjected to the most severe haemorrhagic shock, in groups H45% and TH35%, had significant reductions of factors II, V, VII, VIII and X, down to approximately 45 - 60% of normal. Factor X was most significantly affected, down to 46 ± 4 and 41 ± 3, respectively. However, although there was trend towards reduction of fibrinogen in haemorrhaged animals, neither group developed any statistically significant depletion compared to shams controls.

For haemorrhage severity matched groups (H40%/TH30% and H45%/TH35%), there was generally little further reduction of procoagulant factor activity by the addition of tissue trauma. Similarly, trauma (biltateral hindlimb fracture and laparotomy) alone had negligible effect on procoagulant factor activity. Sham control animals had procoagulant potential activity around 100% of pooled normal plasma control, with exception of heat labile factors V and VIII, which had 89 ± 4% and 90 ± 2%, respectively. 


Fig. 4.10. Procoagulant factor responses to trauma and haemorrhagic shock in the absence of exogenous fluid administration. 4.10a. Trend towards fibrinogen reduction in H45%, TH30% and TH35% groups. 4.10b-f. Generalised reduction in factors II, V, VII, VIII and X in response to haemorrhagic shock, with or without traumatic injury. * = P < 0.05 vs. S

A similar trend was seen in the potential activity levels of anticoagulant/antifibrinolytic factors in response to trauma and haemorrhage (fig. 4.11a-d). Specifically, Protein C levels were approximately halved by 60 minutes of either depth of haemorrhagic shock, with or without trauma. PAI-1 levels were almost completely depleted by the more severe degree of haemorrhagic shock.


Fig. 4.11a-d. Anticoagulant and antifibrinolytic factor responses to trauma and haemorrhagic shock in the absence of exogenous fluid administration.

 4.5.3. Study 3. The coagulation function effects of ex-vivo haemodilution







Fig. 4.12a-b. Coagulation function effects of ex vivo haemodilution with normal saline. 4.12a. PT. 4.12b. aPTT. The dotted lines indicate the potential coagulation function effect of autogenous haemodilution (estimated to be 29%) seen in this model. 

4.5.4. Study 4. The coagulation function effects of ex vivo acidosis










The rat models developed in this experimental investigation successfully reproduce the clinical features of ATC. Acute coagulopathy, as demonstrated by a significant prolongation of the PT and aPTT, developed in response to trauma and haemorrhagic shock within 1 hour. This occurred in the absence of hypothermia or significant crystalloid haemodilution. It provides experimental support for the hypothesis that ATC is an endogenous process that is initiated by injury. This is important because it suggests that trauma induced coagulopathy should be conceived as a dual entity with variable overlap in terms of chronology and pathophysiology: shortly after injury an endogenous acute coagulopathy, ATC, develops as a product of tissue injury and haemorrhage. This is subsequently exacerbated by iatrogenic processes (eg. resuscitation, exposure) and manifests as a systemic acquired coagulopathy.

There is some clinical and experimental data to support this concept. 175 out of the 180 patients who died from traumatic injury at King/Drew Medical Centre in 1981-1982 had a coagulopathy on arrival at the emergency room. This had developed before any fluid or blood products were given (Ordog, Wasserberger et al. 1985). The largest observational study of ATC to date featured 8724 trauma patients  ADDIN EN.CITE (Maegele, Lefering et al. 2007). Within this cohort there were 32 patients who had an acute coagulopathy on arrival at the emergency room despite not receiving any pre-hospital fluid. With increasing administration of pre-hospital crystalloid fluid there was a dose dependent increase in the incidence of coagulopathy  ADDIN EN.CITE (Maegele, Lefering et al. 2007). In a multi-centre animal model pigs were anaesthetised and subjected to femur fracture followed by removal of 60% of their circulating blood and 30 minutes of haemorrhagic shock. This produced a small but significant prolongation of the PT and represents an endogenous acute coagulopathy. They were then resuscitated with 3 times their shed volume in the form of normal saline. This produced a severe metabolic acidosis, haemodilution and systemic acquired coagulopathy with additional prolongation of the PT.

By definition, ATC must involve some degree of tissue injury in order to initiate haemorrhage. However, the relative contribution of tissue injury and haemorrhagic shock to this pathophysiology was unknown and very difficult to determine from clinical studies. Results from study 1 indicated that a combination of significant trauma and haemorrhagic shock were indeed required in order to produce ATC. Either variable in isolation was not sufficient. However, close inspection of the data identified a trend towards coagulopathy in the H group that was not seen in T group. Furthermore, although there was no significant difference in final lactate concentrations between TH40-50 and H, the base deficits, another surrogate marker of systemic hypoperfusion, were significantly higher in TH40-50. Thus, for the same target MAP, addition of traumatic injury may have caused additional shock. Indirect evidence for this is identified in the haematological parameters. The final haemaglobin and haematocrit of TH30-40 animals was significantly higher than H, suggesting they required less blood loss to maintain hypotension. If hypoperfusion was the principle driver of coagulopathy then the increase in base deficits/lactates may have explained the difference in coagulation test prolongations.

Study 2 was performed in an attempt to match H and TH groups in terms of systemic hypoperfusion and answer this question. Using a fixed volume haemorrhage design with intermittent arterial catheterisation also meant that any potential influence of exogenous fluid could be abolished. Lesser fractions of estimated circulating blood volume were haemorrhaged from TH animals to compensate for blood losses at fracture sites. Each fracture was estimated to cause loss of 5% circulating blood volume. This was effective, the haemoglobin and haematocrit of shock-matched groups (H40%/TH30% and H45%/TH35%) were comparable. Importantly, the pH, base deficit and lactate concentrations of these groups were also equivalent. 

Removal of 40% of circulating blood volume, or 30% combined with injury, had no significant effect on coagulation times. However, haemorrhage of 45%, or 35% with injury, produced significant endogenous acute coagulopathy of similar magnitudes. This suggests three things: first, that experimental ATC is driven by systemic hypoperfusion without significant additional independent contribution by tissue injury. Second, that a threshold level of hypoperfusion must be achieved before overt ATC is demonstrated. Third, that the severity of experimental ATC is correlated with the depth of systemic hypoperfusion.

Only 1 previous animal study has examined the independent effects of trauma and haemorrhagic shock on coagulation profile (Chesebro, Rahn et al. 2009). Mice were subjected to tissue injury (laparotomy), haemorrhagic shock (MAP 30 – 40 mmHg for 60 min) or a combination of both. Animals were maintained euthermic and minimal volume of crystalloid was administered (approximately 10% estimated circulating blood volume). Only mice subjected to laparotomy and haemorrhagic shock developed a significant endogenous acute coagulopathy. This occurred despite similar physiology profiles between the shocked groups (pH, base deficit, lactate etc.). The difference in results between these two studies is difficult to reconcile. However, if tissue injury is a major aetiological factor in ATC then it is surprising that a simple midline laparotomy, with division of skin and fibrous tissue only, explains the presence of coagulopathy in the mouse model.

The finding that tissue injury does not independently influence ATC is also at odds with the conclusions of all clinical studies on this subject. Studies by Brohi, Maegele, MacLeod, Hess and Niles all reported an independent correlation between increasing ISS and the prevalence and severity of ATC  ADDIN EN.CITE (Brohi, Singh et al. 2003; MacLeod, Lynn et al. 2003; Brohi, Cohen et al. 2007; Maegele, Lefering et al. 2007; Niles, McLaughlin et al. 2008; Hess, Lindell et al. 2009). Humans and rats may have different coagulation responses to trauma. Thrombin generated by injured tissue may be more important in humans than thrombin produced by tissue factor expression in response to haemorrhagic shock. However, most of these studies are weakened by bias from retrospective data collection. Perhaps a more important explanation could be that ISS is not a direct marker of tissue injury load. It is a non-linear composite score designed to correlate with mortality and morbidity. As such, when used as an indirect marker of trauma load it may be confounded by the effect of haemorrhagic shock. 

The importance of systemic hypoperfusion in the aetiology and pathophysiology of ATC is better supported by scientific literature. In a cohort of 208 trauma patients Brohi et al found that none were coagulopathic without an abnormal base deficit on admission blood gas (Brohi, Cohen et al. 2007). In a military study of combat casualties requiring massive transfusion Niles et al analysed the admission base deficit for its correlation with INR. This relationship was then compared with the relationship between INR and ISS. The correlation coefficient between INR and base deficit was 0.45. This relationship was compared with the correlation between INR and ISS. These were not as closely related at 0.12. Thus, the correlation between base deficit and INR was three times the strength of the association between INR and ISS. There was not any interaction found between these three variables. Wafaisade et al retrospectively studied a multicentre trauma registry for independent risk factors associated with ATC in 1987 patients (Wafaisade, Wutzler et al. 2010). Multivariate analysis identified an independent positive dose-response between admission base deficit and the prevalence of ATC. Importantly, presence of severe shock (base deficit < 10 mmol/l) had the highest adjusted odds ratio of all risk factors (3.03, CI 1.90 – 4.85, p < 0.0001). This compared with ‘severe injury’ (ISS > 50), which had an adjusted odds ratio of 2.29 (CI 1.53 – 3.43, P < 0.0001) and hypothermia (body temperature < 36 C), which had an odds ratio of 1.9 (CI 1.47 – 2.45, P < 0.0001).

Consistent with the findings of this study, experimental coagulation responses to isolated haemorrhage appear dependent upon the depth (and/or duration) of the shock. For example, haemorrhage of 35 ml (approximately 30% of circulating blood volume) from New Zealand White rabbits, without resuscitation, had negligible effect on both the PT and aPTT (Hardaway, Dixon et al. 1976). Similarly, up to 2 hours of haemorrhage to MAP of 40 mmHg in dogs or baboons produces minimal prolongation of the PT and aPTT  ADDIN EN.CITE (Rutherford, West et al. 1966; Herman, Moquin et al. 1972). However, in both these studies, further blood withdrawal produced a significant prolongation of coagulation times. 

Indeed, there appears to be a biphasic coagulation response to experimental haemorrhagic shock with initial blood loss producing hypercoagulability, which progresses to hypocoagulability as more blood is removed over time (TURPINI and STEFANINI 1959). This is well demonstrated using a non-stimulated silicone clotting time test (Rutherford, West et al. 1966). Early hypercoagulability may not have been observed in this study due to the insensitivity of the coagulation tests used. Reagents for the PT and aPTT contain high concentrations of thromboplastin and kaolin, respectively. Therefore, plasma coagulation may have already been maximally activated by the exogenous stimulants.    

The apparent existence of a hypoperfusion threshold for development of coagulopathy may also be a product of the insensitivity of coagulation tests used to measure it. The PT and aPTT do not correlate linearly with reductions of procoagulant factors. They remain within normal ranges until a single factor activity approaches 30 – 40% (Ciavarella, Reed et al. 1987). The correlation between multiple clotting factor deficiencies and prolongations of PT or aPTT is unknown and, to some extent, will depend upon the specific choice of reagent used. However, it is possible that rats in groups H40% and TH30% did develop coagulation impairment that would have been detected using a more sensitive test. Similarly, there is also some evidence that isolated severe tissue injury does activate the haemostatic system, but not sufficiently to effect global screening tests  ADDIN EN.CITE (Hardaway, Williams et al. 1990).

Coagulation factor analysis identified a generalised reduction of activity in response to haemorrhagic shock, with and without traumatic injury. The magnitude of inhibition was consistent with a previously reported experimental assessment of coagulation factor responses to haemorrhagic shock (Rutherford, West et al. 1966). Four dogs were anaesthetised and haemorrhaged to a MAP of 40 mmHg for 4 hours. Blood samples were taken for coagulation factor analysis at the beginning and end of the experimental period. Factor V was depleted by an average of 53%, factor VIII by 52%, factor IX by 84%, factor X by 41% and factor XI by 64%. It could be inferred that factor IX inhibition was the predominant cause of coagulopathy in these dogs. However, further interpretation of these results is limited by the small sample size and absence of confidence intervals. No single coagulation factor was disproportionately depleted in this rat study.

The relative preservation of fibrinogen after haemorrhagic shock was unexpected and diverges from preceding reports of experimental coagulation responses. For example, in the above canine study fibrinogen was reduced to 48% of original levels, in keeping with the other factors (Rutherford, West et al. 1966). Baboons subjected to 2 hours of haemorrhagic shock (60 mmHg for 1 hour followed by 40 mmHg for the second hour) without resuscitation demonstrated an approximate 33% reduction in fibrinogen (Herman, Moquin et al. 1972). Martini et al performed a porcine study of haemorrhagic shock specifically to analyse fibrinogen metabolism changes (Martini, Chinkes et al. 2005). Removal of 35% of circulating blood volume over 30 min, followed by a further 30 min without resuscitation, produced a reduction in fibrinogen concentration from 185  16 mg/dl to 120  2 mg/dl. Interestingly, this was associated with a small but significant shortening of blood clotting time. Fibrinogen synthesis rate was unchanged during the shock period and losses were attributed to an acute acceleration of degradation. The ELISA used for measurement of fibrinogen in study 2 was rat specific and has been validated in previous studies. Fibrinogen metabolism in response to trauma and/or haemorrhage is uncharacterised in rodents. However, it would appear that acute depletion of fibrinogen is unlikely to be responsible for the acute coagulopathy seen in this model of ATC.

Anticoagulant factors (antithrombin, tissue factor pathway inhibitor and protein C) also demonstrated a general reduction in activity in response to haemorrhagic shock, with or without trauma. The magnitude of their depletion was substantial and occurred within a short period of time. This would exclude impaired synthesis as a significant cause. Rather, their consumption might reflect a state of profound activation of the coagulation system. Indeed, similar depletion is seen in humans and animals in response to septic challenges as part of disseminated intravascular coagulation (Levi 2010). Protein C, once activated, acts in concert with its co-factor protein S to proteolytically degrade the essential coagulation co-factors Va and VIIIa. Antithrombin is the main inhibitor of thrombin and factor X. Tissue factor pathway inhibitor is the main inhibitor of the tissue factor-factor VIIa complex. Through these actions the anticoagulant factors are capable of ‘consuming’ activated procoagulant factors and impeding thrombin generation. High concentrations of circulating activated protein C (from exogenous supplementation) can impair clotting times in rats (Malm, Arnljots et al. 2007). Therefore, it is possible that the functional effects of protein C activation in this rat model might include a quantitative prolongation of PT and aPTT. Consistent with this was an almost complete depletion of PAI-1, a fibrinolysis inhibitor that is neutralised by aPC. However, it is impossible from these results to distinguish the relative contribution of anticoagulant inhibition from other causes and so the degree to which they mediate experimental ATC remains unclear. 

The coagulation impairments seen in study 2 could not have been caused by hypothermia or haemodilution from exogenous fluid administration. Rather, they are probably mediated through a combination of autogenous haemodilution, acidosis and consumption. Autogenous haemodilution occurs after haemorrhage through transcapillary refill in response to reduced intravascular hydrostatic pressure (LISTER, MCNEILL et al. 1963). The drop in haemoglobin and haematocrit seen during haemorrhage is evidence that this occurred in study 2 and it was estimated to be of magnitude 29%. Results from study 3 indicated that this might affect the activity of remaining coagulation factors and part mediate the prolongation of PT (although it is acknowledged that normal saline may not have the same effect on coagulation activity as extracellular fluid). Regardless, with the exception of fibrinogen, all other coagulation factors had a reduction of activity in excess of 29%, suggesting other variables were involved. 

The independent haemostatic effects of spontaneous metabolic acidosis caused by haemorrhagic shock are impossible to model in vivo. They cannot be isolated from associated responses such as autogenous haemodiution and coagulation factor consumption. The aim of study 4 was to examine the effect of induced acidosis on normal rat blood ex vivo. Results indicated that pH in the range 7.15 – 7.25, as seen in groups H40/45% and TH30/35%, had negligible effect per se on clotting times. This is consistent with other experimental studies that found little coagulation effects of induced acidosis, both in vivo and ex vivo, at pH above 7.1  ADDIN EN.CITE (CROWELL and HOUSTON 1961; Dunn, Moore et al. 1979; Dirkmann, Hanke et al. 2008).

Consumption of procoagulant factors occurs secondary to coagulation system activation with rapid, irreversible elimination by their natural inhibitors (Mann 1999). The degree to which the major procoagulant factors were diminished in study 2 is evidence that some consumption probably occurred. Theoretically, this consumption could occur through tissue factor-factor VIIa complex dependent pathways at local sites of tissue injury or by systemic expression of tissue factor on non-injured cells (such as monocytes, platelets etc.). It is possible that tissue injury inflicted on rats in the haemorrhage only groups during tracheotomy and arterial catheterisation is sufficient to activate coagulation and subsequent consumption. However, if that is true then the argument that significant trauma is required to initiate ATC is undermined. Rather, that coagulopathy occurred equally in haemorrhaged animals with and without trauma is experimental evidence that localised exposure of tissue factor is unnecessary for ATC. 





There are significant differences between the coagulation systems of different species (Siller-Matula, Plasenzotti et al. 2008). This creates technical difficulties when trying to model human pathologies and limits the validity of generalisations from the results that they produce. For example, the ‘extrinsic system’ of coagulation in rats is more easily activated by contact. This creates problems during venesection if citrate anticoagulation is not immediately applied and results in a shorter aPTT than seen in humans. In contrast, the PT is longer in rats than humans regardless of the thromboplastin reagent used. 





An endogenous acute coagulopathy developed experimentally in rats in response to severe haemorrhagic shock. This occurred in the absence of exogenous fluid administration or hypothermia. In contrast with clinical reports, the presence of severe tissue injury did not appear to influence the magnitude of this coagulopathy. Therefore, the role of local tissue factor stimulated activation of pro- and anti-coagulant pathways to the pathophysiology of ATC is questioned. 
















































































ATC has been characterised as a condition of systemic anticoagulation and hyperfibrinolysis  ADDIN EN.CITE (Brohi, Cohen et al. 2007; Brohi, Cohen et al. 2008). In these studies a positive correlation was identified between the development of ATC and markers of protein C activation. Protein C has anticoagulant function by degrading activated forms of coagulation factors V and VIII. It also promotes fibrinolysis by de-repressing plasminogen. Increased aPC, in response to tissue injury and hypoperfusion, could theoretically modulate coagulation function after trauma. However, the degree to which it does mediate ATC, if at all, is unknown.

The anticoagulant effect of aPC in trauma victims is difficult to quantify in observational studies as the confounding effects of hypothermia cannot be accurately excluded. Further, although dose-response associations between aPC and ATC can be calculated, there are no agents capable of blocking the protein C pathway in humans in order to determine whether removal of the hypothetical causative factor attenuates or eliminates the pathology.





The objective of this study was to develop a mouse model of ATC and use it to evaluate a potential pathophysiological role of aPC. Specific aims were to test the ability of Mab 1591, a monoclonal mouse specific antibody capable of inhibiting the anticoagulant function of aPC, to attenuate or abolish ATC in this model. Further, to determine whether genetic inhibition of the Protein C pathway, in thrombomodulin ‘knock-in’ mice with thousand-fold reduced capacity to activate Protein C, attenuates experimental ATC.






























Fig. 5.1. The effect of variable anaesthetic doses and timings on respiratory and metabolic parameters (means of n = 3 per dosing schedule).





Inhalatory isoflurane was initially delivered in a 70:30 mixture of nitrous oxide and oxygen. However, it became apparent that sham controls, mice that were anaesthetised and catheterised but not haemorrhaged, developed an abnormal base deficit (-5 to -10 mmol/l). To exclude nitrous oxide induced cardiac depression as the cause of metabolic acidosis the carrier gas was changed to medical air. This did not improve the acidosis but was continued in order to reduce the number of potentially confounding factors. 
















Male C57/B6 mice (Charles River Ltd.), aged 8 – 12 weeks of age, received a standard diet and water ad libitum and were cared for in accordance with the UK Home Office Guidance in the Operation of the Animals (Scientific Procedures) Act 1986. General anaesthesia was induced by spontaneous respiration of 3% isoflurane carried in medical air for 45 seconds. Animals were then placed supine on a heated anaesthesia platform and body temperature was maintained at 37 ± 1 °C by means of a rectal probe attached to a homeothermic blanket (Harvard Apparatus). Maintenance anaesthesia was supplied by a nose cone and waste gas scavenged by negative pressure suction positioned close to the animal. All surgery was performed under 1.5% isoflurane. After surgery, the isoflurane dose was lowered to 0.5 - 1% for the experimental period.

The left carotid artery and external jugular vein of all animals were catheterised with polyethylene tubing (Portex) connected to a pressure transducer (Capto SP 844, AD instruments) and syringe pump (PHD 22/2000, Harvard Apparatus) by means of a 3-way connector. Fluid was continuously infused at a minimum rate of 50 µl per hour through the carotid catheter with supplementary flushes as required in order to maintain patency.  The experimental period commenced immediately after traumatic injury in relevant groups or 7 minutes after completion of catheterisation in groups not sustaining trauma (the mean time taken to complete traumatisation). Sham control animals (S) were anaesthetised and monitored. Animals in haemorrhagic shock groups were rapidly bled to the target MAP over 5 minutes and this pressure was maintained by further withdrawals as necessary during the experimental period.  

5.4.2. Terminal blood sampling and coagulation function analysis

At the end of the experimental period 50 l of blood/saline was aspirated from the carotid catheter of all animals and discarded. A further 200 l was then aspirated into a 1 ml syringe pre-filled with 20 l of 3.2% sodium citrate (Sigma,UK). Additional citrate was added to achieve a 1:9 final concentration. 1 mmol Benzamidine protease inhibitor was added to 30 µl samples for measurement of plasma aPC concentration. Lactate was measured (Accutrend, Roche) with 20 l plasma samples and the remainder was centrifuged at 3500g for 15 mins at room temperature. Plasma supernatants were aspirated immediately, snap frozen in liquid nitrogen and stored at -80°C.  

Coagulation analysis was performed on a single channel thrombotrack coagulometer (Axis-Shield) using modified sample volumes. PT was measured by incubating 100 l of Neoplastine CI reagent (Stago) for 3 min followed by the addition of 50 l plasma sample. APTT was performed by incubating 50 l of C.K. Prest reagent (Stago) with 50 l of plasma sample for 3 min followed by addition of 50 l of 0.025mmol calcium chloride (Dade Behring, UK). 
Activated protein C levels were measured in the laboratory of Professor MJ Cohen (University of California, San Francisco, USA) using an assay specific for the activated form of PC (Chesebro, Rahn et al. 2009). Briefly, a 96-well vinyl plate was coated overnight at 4°C with monoclonal antibody AMGDPC 1587 at 5 µg/mL in plating buffer (0.02 M Tris, 0.1 M NaCl, pH 7.5). Plates were then blocked with blocking buffer (0.02 M Tris, 0.1 M NaCl, 1% bovine serum albumin, pH 7.5). Standard dilutions of mouse aPC and mouse plasma samples were loaded onto the plate and incubated at room temperature for 2 h on a 150-rpm rocker. Plates were washed with wash buffer (0.02 M Tris, 0.1 M NaCl, 0.05% Tween, pH 7.5). Spectrazyme PCA at 1 mM in plating buffer was added and incubated at 37°C for 24 h. Absorbance was measured at 405 nm with sample concentration derived from standard curve.

5.4.3. Study 1. Effects of increasing severities of tissue injury and haemorrhagic shock in a murine model of ATC

Groups of n = 10 mice were subjected to increasing severities of trauma and/or haemorrhage. Group TH1 received a 2 cm paramedian laparotomy, closed in one layer with 7 mm surgical clips (Haravard Apparatus), followed by haemorrhagic shock to MAP of 30 – 40 mmHg for 60 min. Group TH2 received a laparotomy followed by haemorrhagic shock to MAP 30 – 40 mmHg for 90 min. Group TH3 received a laparotomy followed by haemorrhagic shock to 25 – 35 mmH for 60 min. Group TH4 received a laparotomy and bilateral thigh crushes using haemostatic artery clips, followed by haemorrhagic shock to MAP 30 – 40 mmHg for 60 min. Group TH5 received a laparotomy, bilateral thigh crushes and bilateral closed tibia/fibula, using 3-point distraction technique with haemostatic clips, followed by haemorrhagic shock to MAP 30 - 40 mmHg for 60 min. Group TH6, received a laparotomy and bilateral tibia/fibula fracture followed by haemorrhagic shock to MAP 25 – 35 mmHg for 60 min.

5.4.4. Study 2. Protein C pathway activation in a murine model of ATC

38 mice were assigned to 4 groups. Sham control (S) animals were anaesthetised and monitored. Mice in an isolated trauma group (T) received a paramedian laparotomy without haemorrhage. Mice in an isolated haemorrhage group (H) were bled to a MAP of 25 – 30 mmHg for the experimental period (60 min). Trauma and haemorrhage animals (TH) received a laparotomy and were bled to MAP of 25 – 30 mmHg.

5.4.5. Study 3. Immunochemical inhibition of the Protein C pathway in a murine model of ATC

28 C57/B6 mice aged 8 – 12 weeks were randomised to receive 4mg/kg of either Monoclonal Antibody 1591 (kind gift of Dr Charles Esmon, Howard Hughes Medical Institute, Oklahoma, USA) or Isotype Control Antibody (R&D Systems, Abingdon, UK) via jugular catheter immediately prior to undergoing laparotomy and haemorrhagic shock to MAP 25 – 30 mmHg for 60 min. This was performed blinded, with knowledge of treatment groups only available after all experiments and coagulation analysis had been completed.

5.4.6. Study 4. Transgenic inhibition of the Protein C pathway in a murine model of ATC

TMPro ‘knock-in’ mice with thousand-fold reduced capacity to activate protein C were the kind gift of Dr Hartmut Weiler (Winsconsin Blood Centre, USA). These were bred from C57/B6 mice after targeted mutagenesis with a single single amino acid substitution (Glu404Pro) on alleles coding for the thrombomodulin receptor. 
Genotyping at the Genome Centre (Queen Mary University, London, UK) confirmed each subject a homozygote. 
















5.6.1. Study 1. Effects of increasing severities of tissue injury and haemorrhagic shock in a murine model of ATC

All 10 mice in groups S, TH1, TH2, TH4 and TH5 survived to the end of the experimental period. 3 mice died during the haemorrhagic shock phase in group TH3. Mortality was 100% during the haemorrhagic shock phase in group TH6.




Fig. 5.3a-c. Lactate and coagulation parameters in response to increasing trauma and haemorrhagic shock. 3a. Venous lactate concentration. 5.3b. PT. 5.3c. aPTT. Only a combination of laparotomy and haemorrhagic shock to 25 – 35 mmHg produced a significant prolongation of coagulation times. * = P < 0.05 compared with (S).

5.6.2. Study 2. Protein C pathway activation in a murine model of ATC

All 10 mice in groups (S) and (T) survived to the end of the experimental period. 2 of 12 mice in group (H) and 3 of 18 in group (TH) expired during the haemorrhagic shock phase and were not included for analysis. 

Trauma alone had negligible effect on circulating concentrations of lactate and was not associated with any prolongation of the coagulation times. Haemorrhage to 25 – 30 mmHg for 60 min produced a significant lactataemia and was associated with significant prolongations of the PT and aPTT (Lactate: H = 5.9 ± 0.7 mmol/l vs. S = 2.2 ±0.1 mmol/l, CI = 1.9 – 5.6 mmol/l; PT: H = 14.7 ± 0.4 s vs. S = 11.7 ± 0.3, CI = 1.4 – 4.5 s; aPTT: TH = 35.0 ± 2.6 s vs. 22.0 ± 0.7 s, CI = 2.7 – 23.3 s). For the same haemorrhage MAP target, addition of tissue injury produced a consistent trend towards increased lactate concentrations and more prolonged coagulation times. However, statistically, these groups were not significantly different (Lactate: TH = 6.6 ± 0.6 mmol/l vs. H = 5.9 ± 0.7 mmol/l, CI = -2.6 – 1.2 mmol/l; PT: TH = 15.7 ± 0.7 s vs. H = 14.7 ± 0.4 s, CI = -2.7 – 0.7 s; aPTT: TH = 37.9 ± 3.6 s vs. H = 35.0 ± 2.6 s, CI = -13.6 – 7.8) (fig. 5.4a-c). 
 
Fig. 5.4a-c. Lactate and coagulation parameters in response to trauma and haemorrhagic shock. Haemorrhagic shock, to a MAP of 25 – 30 mmHg for 60 min with or without trauma, produces a significant lactataemia with prolongation of the coagulation times.  * = P < 0.05 compared with (S).

Trauma alone had no significant effect on circulating concentrations of aPC in this mouse model (fig. 5.5). Although haemorrhagic shock was associated with triple –fold increase in aPC levels, this difference did not meet statistical significance compared with sham controls (H = 2 ± 0.3 ng/ml vs. S = 0.6 ± 0.04 ng/ml, CI = -3.0 – 0.3). However, combination of trauma and haemorrhagic shock did produce a statistically significant six-fold increase in aPC (TH = 4.2 ± 0.6 ng/ml vs. 0.6 ± 0.04 ng/ml, CI = 2.0 – 5.0 ng/ml), 


Fig. 5.5. Murine aPC concentrations in response to trauma and haemorrhagic shock.

5.6.3. Study 3. Pharmacological inhibition of the Protein C pathway in a murine model of ATC

All animals survived to the initiation of haemorrhagic shock. 4 mice from each treatment group died before the end of the experimental period. Therefore, data analysis was performed on n = 10 mice from each group. Lactate concentration and coagulation function test results were compared with results for the sham control group (S) from study 2. Trauma and haemorrhagic shock for 60 minutes produced a significant lactataemia that was similar in both treatment groups (Mab 1591 = 7.0 ± 0.mmol/l vs. Isotype Control = 6.9 ± 0.5 mmol/l, CI = -1.9 – 1.7 mmol/l). Trauma and haemorrhage after pre-treatment with Isotype Control produced a significant prolongation of both the PT and aPTT (PT: Isotype Control = 16.5 ± 0.8 s vs. Sham = 11.7 ± 0.3 s, CI = 2.9 – 6.6 s; aPTT: Isotype Control = 56.7 ± 8.3 s vs. Sham = 22.0 ± 0.7 s, CI = 16.5 – 52.8 s). This was significantly attenuated by pre-treatment with Monoclonal Antibody 1591 (PT: Mab 1591 = 14.2 ± 0.4 s vs. Isotype Control = 16.5 0.8 s, CI = 0.4 – 4.1 s; aPTT: Mab 1591 = 36.7 ± 2.3 s vs. Isotype Control = 56.7 ± 8.3 s, CI = 1.8 – 38.1 s) (fig. 5.6a-c).     

Fig. 5.6a-c. Lactate and coagulation parameters in response to trauma and haemorrhagic shock. 5.6a. Lactate concentrations were similar between the two treatment groups at the end of trauma and haemorrhagic shock. 5.6b.Pre-treatment with Mab 1591 significantly attenuated the PT prolongation seen in response to trauma and haemorrhagic shock. 5.6c. Pre-treatment with Mab 1591 abolished the aPTT prolongation seen in response to trauma and haemorrhagic shock. There was no statistical difference between mice in the sham control group and those pre-treated with Mab 1591. * = P < 0.05 compared with Sham.  = P < 0.05 compared with Isotype Control.

5.6.4. Study 4. Transgenic inhibition of the Protein C pathway in a murine model of ATC

All animals survived to the initiation of haemorrhagic shock. 8 mice from the TMPro TH group and 5 from the C57/B6 TH group died before the end of the 60 min experimental period (P < 0.05).  Therefore, data analysis was performed on n = 12 mice from each group. All 12 sham control animals of both genotypes survived the experimental period and were included for analysis. 

Compared to C57/B6 sham mice, TMpro sham mice had similar lactate concentration and coagulation test times after 60 min of anaesthesia and monitoring (Lactate: TMpro sham = 2.2 ± 0.2 mmol/l vs. 2.2 ± 0.2 mmol/l, CI = -1.1 – 1.2 mmol/l. PT: TMpro sham = 10.7 ± 0.3 s vs. C57B6 sham = 11.2 ± 0.1 s, CI = -0.7 – 1.7 s. aPTT: 22.3 ± 0.5 s vs. C57B6 sham = 23.2 ± 0.4 s, CI = -7.2 – 9.0 s)(fig. 5.7a-c). Trauma and haemorrhagic shock for 60 min produced a lactataemia that was comparable in both genotypes (TMpro TH = 8.1 ± 0.4 mmol/l vs. C57/B6 TH = 8.5 ± 0.3 mmol/l, CI = -0.7 – 1.5). This was accompanied by statistically significant prolongations of PT and aPTT. However, the magnitude of acute coagulopathy seen in TMpro TH mice was significantly less than in C57/B6 TH mice (PT: TMpro TH = 13.0 ± 0 .4 s vs. C57/B6 TH = 15.2 ± 0.4 s, CI = 0.1 - 4.0 s. aPTT: TMpro TH = 30.6 ± 2.0 s vs. C57/B6 TH = 40.8 ± 3.5 s, CI = 2.2 - 18.2 s).






Mice are challenging specie with which to model ATC. The surgery is made difficult by the size of anatomy and circulating blood volume limits the availability of samples for assay, particularly in a non-resuscitative model. Furthermore, they seem more resistant to acute coagulopathy than rats as evidenced by the profound hypotension and high lactataemia required in order to prolong coagulation times. Combined, these issues result in a relatively high mortality rate for this model.

Nevertheless, mice have been shown to develop an acute endogenous coagulopathy in the absence of hypothermia or haemodilution from significant fluid administration. As discovered in rats, this appeared to associate with the depth of hypoperfusion more than the degree of traumatic injury. Indeed, study 2 demonstrated that addition of soft tissue injury to haemorrhagic shock did not produce any further prolongation of clotting times. This finding contrasts with the results of the only published model of murine ATC (Chesebro, Rahn et al. 2009). They reported that acute coagulopathy was only observed when in mice when they were subjected to laparotomy and haemorrhagic shock (target MAP 30 – 40 mmHg). Haemorrhage alone produced no effect on the coagulation profile. 

Potential explanations for the disparate results between the two models may be found in the differences of methodology. For example, Chesebro et al induced and maintained haemorrhagic shock in the animals whilst they were sedated. The model presented in this chapter featured general anaesthesia throughout. Theoretically, addition of tissue injury in Chesebro’s model could have elicited hormonal and neurochemical pain responses that modulated coagulation changes. However, if this were the case then it is surprising that conscious haemorrhagic shock did not elicit the same effect, particularly as the markers of systemic hypoperfusion were similar between the two groups. 

Another potential explanation is the different methods used for coagulation testing. All mice in this chapter had a separate PT and aPTT measured using a digital coagulometer with modified plasma sample volumes. Due to restrictions on minimum sample volumes required, Chesebro et al had to combine plasma samples from more than one mouse in each group (personal communication). In theory, samples from mice without coagulopathy could compensate for those with clotting impairment, due to the non-linear response of PT/aPTT to clotting factor deficiencies. However, why this effect should apply to the group subjected to haemorrhagic shock alone and not to those with additional laparotomy is unknown. The differences may simply be due to chance in experiments with small sample sizes and where relatively small increments in haemorrhagic shock targets (eg. from MAP 30 – 40 mmHg down to 25 – 35 mmHg, see study 1) make the difference between the presence and absence of overt coagulopathy. 

Acute coagulopathy was observed to associate with a trend towards increased aPC in haemorrhaged mice. With addition of laparotomy this association trend reached statistical significance. The positive direction of this association is important as it occurred despite potential diminution by consumption and haemodilution. It is also supportive for the hypothesis that increased circulating aPC is mechanistically involved in the pathophysiology of ATC. However, three aspects of these results moderate this assertion. 

Firstly, if aPC were the predominant mechanism for the acute coagulopathy seen in H and TH groups, it would be reasonable to expect a similar aPC response in both. This was not the case. TH mice had an aPC rise to approximately double the concentration of H mice. Secondly, final concentrations of aPC measured in this study were considerably lower than that reported by Chesebro et al. They reported concentrations of approximately 2 ng/ml in sham control mice and 13 ng/ml in trauma-haemorrhaged mice. In this study those values were 0.6 ng/ml and 4.2 ng/ml, respectively. Part of this discrepancy could be a product of differences between the mice, anaesthetic and model protocol used. However, the normal range for mouse aPC has been reported to be between 1.06 and 5.38 ng/ml in healthy mice (Fernández, Lentz et al. 2006). Therefore, it would appear that inhibition of aPC decay with Benzamindine 1 mM in this study might have been sub-optimal. Nevertheless, this limitation could be expected to affect all samples equally and, therefore, the qualitative direction of aPC concentrations is considered reliable.

Finally, there is some doubt that the magnitude of aPC rise in either study would be sufficient to have a functional effect on simple coagulation tests. Infusion of recombinant activated protein C (drotrecogin alfa) into healthy humans at the recommended therapeutic dose (24 g/kg/h) produces a steady state circulating concentration of 60 – 80 ng/ml  ADDIN EN.CITE (Derhaschnig, Reiter et al. 2003). It is associated with a prolongation of the aPTT by 10 – 20%. The effect of this exogenous aPC on the PT is negligible and this test is not routinely monitored for pharmacovigilance. For example, incubation of normal human plasma with aPC at a final concentration of 2 g/ml produces a statistically insignificant prolongation of the PT from 14.5 to 15.5 s  ADDIN EN.CITE (Koestenberger, Cvirn et al. 2004). In vivo infusion of recombinant human aPC into Sprague-Dawley albino rats increased both the PT (from approximately 36 to 39 s) and the aPTT (from 21 to 30 s) within a few minutes. However, this was at a dose (0.8 mg/kg) that could be expected to produce circulating concentrations in the region of 50 nM (2,800 ng/ml). 

The anticoagulant effects of aPC in vivo may vary depending upon the host species, whether it is endogenously produced or from an exogenous (xenogenic) source, and the state of the haemostatic system at the time of action. For example, anticoagulant effects on the PT and aPTT may be more pronounced in blood that is already impaired by haemodilution and consumption than in normal blood. Therefore, functional effects of inhibiting the protein C pathway during trauma and haemorrhage are essential to evaluate the causal role of aPC in ATC.

TMpro mice were raised on a background of C57/B6 and underwent single amino acid substitution (Glu404Pro) in both alleles coding for the transmembrane thrombomodulin receptor  ADDIN EN.CITE (Weiler-Guettler, Christie et al. 1998). This produced a conformational change in receptor structure and 100-fold reduced ability to bind thrombin. Subsequently, whilst they retain embryonic viability, the aPC generating capacity of these mice is effectively abolished. 

Absence of the anti-inflammatory properties of aPC could be expected to associate with worse morbidity and mortality in response to experimental trauma and/or haemorrhagic shock (Weiler, Kerlin et al. 2004). Although organ function was not measured in this study an increase in mortality was observed. This is notable as it raises the possibility that the TMpro mice that were most physiologically challenged by the trauma and haemorrhage, and therefore most likely to develop coagulopathy, died before the end of the experimental period. This might have produced a survivor bias towards lesser coagulopathy in the TMpro cohort. However, the equivalence of lactataemia between the two groups would suggest that this effect did not occur. The difference in mortality is consistent with the findings of Chesebro et al in which inhibition of the anti-inflammatory and cytoprotective properties of aPC, using monoclonal antibody 1609, produced 100% mortality within 45 minutes of shock. Survival of 10 out of 18 TMpro mice in this model would suggest that only minimal concentrations of aPC are required to preserve some cytoprotective function. Measurement of residual aPC at the end of the shock period may have confirmed this.

Transgenic inhibition of aPC generation is associated with significant attenuation of the acute coagulopathy seen in response to trauma and haemorrhagic shock. This experimental finding is strongly supportive of the hypothesis that anticoagulant aPC contributes to the endogenous acute haemostatic dysfunction seen in trauma patients.
At least two mechanisms have been identified through which this effect may occur. Firstly, aPC inactivates factors Va and VIIIa by proteolytic cleavage. Inactivation of factor Va is a complex process involving multiple cleavage sites (Kalafatis, Rand et al. 1994). The critical events are the cleavage at Arg506 and Arg306, which reduce affinity of factor Va for factor Xa (Gale, Xu et al. 2002). Cleavage at Arg506 is rapid and much faster than cleavage at Arg306, but it only partially inactivates factor Va, whereas cleavage at Arg306 results in the complete inactivation of factor Va. The importance of factor Va inactivation is observed in patients carrying one of three known mutations in factor V (Arg506Gln, factor V Leiden; Arg306Thr, factor V Cambridge and Arg306Gly, factor V Hong Kong) that render factor Va resistant to APC inactivation, contributing to an increased thrombotic risk. Proteolytic inactivation of factor VIIIa by aPC occurs at Arg336 and Arg562, two residues that are homologous to Arg306 and Arg506 in factor Va. Unlike for factor Va inactivation by aPC, there is no sequential kinetic order of cleavage in factor VIIIa inactivation as cleavage at either Arg336 or Arg562 results in near complete inactivation of factor VIIIa (Mosnier and Griffin 2006). 

Factor Va inhibition maybe more important than factor VIIIa to the pathophysiology of ATC because, as a component of the ‘common’ pathway of coagulation, profound deficiency will be reflected in both the PT and aPTT. Further, factor VIIIa has a short half-life (2 min) due to spontaneous dissociation of constituent protein chains. This calls into question the pathophysiological relevance of its inhibition by aPC. 

An additional function of aPC is the enhancement of fibrinolytic activity by forming tight complexes with PAI-1 (Sakata, Loskutoff et al. 1986). Although this leads to the simultaneous inactivation of aPC, it decreases PAI-1 concentrations and relieves tissue plasminogen activator from inhibitory control. Further, aPC mediated reduction in thrombin generation contributes to decreased thrombin activatable fibrinolysis inhibitor (TAFI) activation with subsequent de-repression of fibrinolysis. The clinical importance of clot lysis control mechanisms has recently been identified by a randomized controlled trial of Tranexamic Acid in bleeding trauma patients  ADDIN EN.CITE (Shakur, Roberts et al. 2010). Early treatment after injury produced a significant reduction in mortality, particularly in the subgroup that died from haemorrhage (Roberts, Shakur et al. 2011). However, the degree to which fibrinolysis, particularly that influenced by aPC, mediates ATC is essentially unknown. In this mouse study ATC was defined by a significant prolongation of PT and aPTT tests. These measure the first 4% of thrombin generation. Therefore, it is unlikely that hyperfibrinolysis plays a significant role in the pathophysiology of ATC in this model. 

5.8.	     Limitations

Evaluation of the protein C pathway in response to trauma and/or haemorrhagic shock was not complete in this study. As mentioned, inhibition of aPC in mice subjected to biochemical or transgenic manipulation was not confirmed. Other downstream effects of aPC, such as factor Va, VIIIa, PAI-1 and TAFI were not analysed. Similarly, a dose-response effect between aPC concentrations and coagulation test times was not shown. Therefore, it cannot be concluded with absolute certainty the degree to which aPC contributed to the experimental ATC observed.

5.8. 	     Conclusions










































The scientific investigation detailed in this thesis makes significant contribution to the body of knowledge regarding the aetiology and pathophysiology of ATC. Chapter 2 reported the results of a large multi-centre observational study of the prevalence and clinical importance of different haemostatic impairments after injury. Using a new, clinically relevant definition (PTr > 1.2), ATC was found to occur in up to 36% of trauma patients and correlated with the combined severities of injury and tissue hypoperfusion. Chapter 3 identified a general paucity of contemporary animal models with which to study this newly identified entity. In particular, most published models failed to feature a combination of tissue injury and shock as the initiating factors of coagulopathy. Chapter 4 described the development and characterisation of a clinically relevant experimental rat model of ATC. Acute coagulopathy was confirmed to occur in the absence of hypothermia or crystalloid haemodilution, the conventional supposed causes of TIC. This endogenous process associated with a degree of autogenous haemodilution and modest global clotting factor dysfunction. Lastly, chapter 5 explored the role of the anticoagulant protein C pathway in the pathophysiology of ATC using a mouse model. Increased protein C activation was observed to occur in response to trauma and haemorrhagic shock and inhibition of this pathway using biochemical and transgenic methods produced significant attenuation of the resultant coagulopathy.

6.2. 	Clinical importance 

The profound effect of ATC on the morbidity and mortality of trauma patients underlines the social and scientific imperative for better understanding of this condition. There is an engaging and important debate about the dominant mechanism of ATC and, accordingly, how best to treat it; two principle hypotheses have emerged. Gando et al eschew the term ‘ATC’ and propose that early coagulopathy after trauma represents DIC with a “ﬁbrinolytic” phenotype (Gando, Sawamura et al. 2011). Ergo, activation of coagulation is neither localised to areas of tissue injury nor wholly stimulated by tissue factor originating from it. Brohi et al contend that coagulation factor consumption caused by systemic activation of coagulation is not predominant. Rather, ATC is characterised by systemic anticoagulation and hyperfibrinolysis from aPC catalysed by thrombin-thrombomodulin complexes generated exclusively at sites of tissue injury (Brohi, Cohen et al. 2008).

Diagnosis of DIC is complex and the scoring systems involved require results of multiple assays, some of which are not routinely performed in clinical practice. None of the studies performed in this thesis are able to support or refute the ability of DIC scoring systems to diagnose or predict prognosis in subjects with an acute coagulopathy. This was not a primary aim of this thesis and insufficient varieties of coagulation assays were performed to make this possible. However, some evidence from the experimental models suggests that the process of disseminated intravascular coagulation, that is systemic activation of coagulation with a degree of coagulation factor consumption, may occur with blood loss after trauma. An acute coagulopathy was seen in response to severe haemorrhagic shock in both rats and mice. In the absence of significant tissue injury (assuming that blood vessel catheterisation and tracheotomy do not constitute this) this could not have occurred by local tissue factor expression at the sites of mechanical endothelial disruption. Alternate hypotheses for haemorrhage-induced coagulopathy include the effect of acidosis and autogenous haemodilution in vivo. However, knowing that ischaemia causes inflammation (Kosieradzki and Rowiński 2008) and that cytokines can activate a range of haemostatic factors (Levi and van der Poll 2010), it seems likely that systemic hypoperfusion could initiate the process of DIC.

The divergence of clinical and experimental findings in this thesis, with respect to the ability of isolated haemorrhagic shock to produce an acute endogenous coagulopathy, is an important medical issue to resolve. Unfortunately, in the current absence of a clinical biomarker for mechanical tissue disruption it would not be possible to determine this with a prospective trauma study. However, if confirmed it would suggest that the recent therapies found to be of benefit in the resuscitation of trauma patients (eg. increased ratios of FFP:PRBC, Tranexamic Acid) may improve outcomes for resuscitation of a range of haemorrhagic conditions (eg. ruptured aneurysms, post-natal haemorrhage). 





A limitation that recurs throughout this thesis is the failure to comprehensively characterise ATC in relation to all components of haemostasis. For example, screening tests of coagulation were used in both the clinical and experimental studies to define and diagnose ATC. Thromboelastography was not used. Further, the considerable role of platelets to clot construction and lysis has been neglected. Therefore, the picture that we have of haemostasis after trauma in vivo is incomplete. This was part strategic and part necessity. 

ATC has only recently been well described and most research publications have used screening tests of coagulation to diagnose it. Therefore, in order to produce a ‘gold-standard’ definition it was important to use a test that was ubiquitously available and understood by all disciplines of the medical community. As the value of thromboelastography becomes appreciated with increasing use there is scope to better describe and define ATC using this modality. The same argument is applicable to the experimental studies presented in this thesis. In order to claim that human ATC had been effectively modeled it was essential to measure it using tests currently used in the clinical setting.

The contribution of reduced platelet number and function to impaired haemostasis after trauma is poorly understood and probably underestimated (Davenport and Brohi 2009). It would have been desirable to evaluate this in the experimental models of ATC. However, having decided to use coagulation screening tests to measure ATC, which are performed with platelet poor plasma, it would have been difficult to determine what effect any change in platelet function or number was having on the coagulopathy. Further, the cost of these tests and the volume of blood required was prohibitive for a study of coagulation using non-resuscitative small animal models. 






Having established the role of aPC in the pathophysiology of ATC it remains to be determined the mechanism by which this occurs. The relative importance of factor Va inhibition could be explored by studying the putative protection from ATC that factor V Leiden might offer. This could be performed in a clinical cohort or case-control study. Alternatively, factor V Leiden mice have been developed that demonstrate resistance to aPC  ADDIN EN.CITE (Cui, Eitzman et al. 2000). If aPC modulates ATC by preferentially depleting factor V then it would be very interesting to see whether, experimentally and/or clinically, factor V replacement is capable of preventing or treating ATC. Further, the potential effect of aPC on hyperfibrinolysis after injury could be explored by inhibiting fibrinolyis using known agents such as tranexamic acid or aminocaproic acid. 
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